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Background: The prevalence of obstructive airway diseases such as asthma and chronic obstructive 
pulmonary disease (COPD) has increased significantly in recent decades, concurrently with 
increasing mental health problems worldwide. However, the underlying mechanisms especially the 
relative contribution of psychological stress to the psychiatric co-morbidities and functioning 
impairment observed in obstructive airway diseases are not well elucidated. 
Objective: This study aims to explore the stress-airway obstruction association in adolescent, adult 
and elderly individuals, and the underlying role of neuropeptide Y (NPY) through a cross-sectional 
clinical study, a clinical follow-up study and population-based studies. 
Methods: A systematic meta-analysis and meta-regression was performed about the prevalence of 
anxiety and depressive symptoms in adolescents with asthma in Study I. The stress-asthma link was 
investigated in a clinical study (Study II) of adolescents with well controlled asthma (n = 137), 
poorly controlled asthma (n = 61), and healthy neighbourhood controls (n = 171). Questionnaires 
were administered to explore the symptom profile of specific anxiety and depressive comorbidity 
(panic attacks, social phobia, generalized anxiety, obsession and compulsion, separation anxiety, 
depression, total anxiety and total internalizing symptoms (anxiety and depressive)) in adolescents 
with asthma and the role of perceived stress in explaining the association between asthma and 
psychiatric comorbidity. In Study III, data in a nationally representative sample of Singaporean 
adults aged 20-59 (n = 2847) were analysed for asthma, other chronic physical conditions (e.g., 
coronary heart disease, stroke, lipid abnormalities), and no chronic physical conditions. Participants 
were assessed for stressful life events, psychiatric disorders, and quality of life. Population-based 
data were analysed for a sample (n = 497) of older persons aged 65 and above (Singapore 
Longitudinal Ageing Study (SLAS), Study IV) with airway obstruction (post-bronchodilatation 
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FEV1/FVC < 0.70, n = 136) or without airway obstruction (n = 277). The main effects of stressful 
life events and airway obstruction, and their interaction, on measures of pulmonary function, 
depressive symptoms (Geriatric Depression Scale), cognitive function (Cognitive Failures 
Questionnaire and Mini-Mental State Examination), and quality of life were investigated. Study V 
investigated the association of measures of psychological and biological stress with T helper cell type 
(Th)2 expression of Interleukin-4 (IL-4), a cytokine marker of allergic airway inflammation in 
asthma and the potential mediating role of NPY in this association among 70 young adult (21-35 
years old) acutely exacerbated and non-exacerbated chronic asthma patients, and 69 age- and gender-
matched healthy controls. The participants were assessed for the levels of perceived stress (Perceived 
Stress Scale), hypothalamo-pituitary-adrenal (HPA) hormones, adrenocorticotropic hormone 
(ACTH), adrenaline (A), noradrenaline (NA), cortisol, NPY and IL-4 (measured at baseline and 12-
month follow-up). 
Results: Study I showed that the aggregate prevalence of depressive and anxiety symptoms was 
significantly higher among 3,546 adolescents with asthma than that of 24,884 healthy controls 
(Depression: 0.27; 95% CI: 0.18.6-0.39 vs. 0.13; 95% CI: 0.09-0.19; Anxiety: 0.33; 95% CI: 0.19-
0.52 vs. 0.21; 95% CI: 0.12-0.33). The risk of developing depression and anxiety was significantly 
higher among adolescents with asthma when compared with the healthy controls (depression: OR = 
2.09, p < 0.001; anxiety: OR = 1.83, p < 0.001). Meta-regression revealed that the proportions of 
Caucasian (p < 0.01) and smokers (p < 0.001) were significant moderators which explained the 
significant heterogeneity when comparing the risk of developing depressive symptoms among 
adolescent asthma patients versus the healthy controls while age, gender and severity of asthma were 
not significant. In Study II, adolescents with poorly controlled asthma, compared with well 
controlled asthma patients and the healthy controls, had higher scores of depression (p = 0.006), 
panic attacks (p = 0.002), total anxiety (p = 0.038) and total internalizing symptoms (p = 0.017), as 
XI 
 
well as perceived stress (p = 0.022), after adjusting for potential confounders. Perceived stress 
explained to a great extent the psychiatric comorbidity scores both in the whole sample and in asthma 
patients. Study III found that the asthma group reported significantly more stressful life events than 
individuals with other chronic medical conditions (OR = 2.93) and the healthy controls (OR = 4.88).  
Among individuals with asthma, stressful life events contributed significantly towards increased 
psychiatric comorbidity and worse SF-12 Mental Component Summary functioning scores. In the 
elderly (Study IV), stressful life events were found to be associated with more depressive symptoms 
(Main effects stress: F = 64.500, p < 0.001; Main effects airway obstruction: F = 2.353, p = 0.126; Interaction: 
F = 10.970, p = 0.001) and worse physical (Main effects stress: F = 7.054, p = 0.008; Main effects airway 
obstruction: F = 0.432, p = 0.512; Interaction: F = 4.055, p = 0.045) and mental functions (Main effects 
stress: F = 14.710, p < 0.001; Main effects airway obstruction: F = 0.659, p = 0.417; Interaction: F = 4.538, p 
= 0.034) in participants with airway obstruction than in those without airway obstruction after 
adjusting for potential confounders. In Study V, higher levels of perceived stress, corroborated by 
elevated levels of ACTH, NA, A, derived HPA stress index, and depressed cortisol were observed in 
patients with asthma than with healthy controls (p < 0.05). NPY levels congruent with chronic stress 
exposure was lower in asthma patients versus controls (p = 0.01). Among asthma patients, perceived 
stress and NPY were significantly and positively associated with elevated IL-4 levels at baseline and 
1-year follow up. NPY significantly mediated the association of psychological stress with IL-4 
(Sobel tests: p = 0.033, baseline IL-4; p = 0.032, IL-4 one year later). The HPA index measure of 
transient biological stress, independent of NPY, was a significant predictor of IL-4 at baseline but not 
at one-year follow up. 
Conclusions: Results of the present thesis suggest the pivotal role of psychological stress to the 
association of psychological symptoms and obstructive airway diseases. NPY may be a plausible 
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neuroendocrine mediator for the persistent effect of perceived stress on heightening Th2 immune and 
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CHAPTER 1 INTRODUCTION 
Asthma affects over 300 million people worldwide. Chronic obstructive pulmonary disease (COPD) 
will rank the fifth in the global burden of disease by 2020. 1 The increased prevalence of obstructive 
airway diseases is occurring concurrently with increasing mental health problems and impaired 
quality of life. The connection between stress and airway obstruction has vast aetiological 
significance, and may represent the next leap in advancing knowledge about airway disease aetiology, 
prevention and treatment. This thesis focused on aspects of the contribution of psychological stress to 
the psychiatric comorbidity of airway obstruction in different age groups including adolescent, adult 
and the elderly individuals, as well as the role of neuropeptide Y (NPY) in mediating the persistent 
effect of perceived stress on heightening T helper cell type (Th)2 immune and inflammatory 
responses in asthma. Research into the role of neuropeptides in the inter-individual variability in 
stress-airway obstruction connection will greatly enhance the understanding of asthma 
pathophysiology from a psycho-neuro-immunological perspective. Chapter 1 presented the general 
background and context of the current study. More detailed literature review was covered in Chapter 
2.           
 
1.1 Obstructive airway disease and its burden to society 
Obstructive airway diseases such as asthma and COPD are a category of respiratory diseases 
characterized by airway obstruction. It is generally distinguished by inflamed and easily collapsible 
airways, airflow obstruction, problems with exhaling and frequent physician and Emergency 
Medicine Department (EMD) visits and hospitalizations. 2 Obstructive airway disease has shown 
increasing prevalence in various populations. Among the adult population, the reported prevalence of 
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asthma varies from 1.9% in Greece to 18.4% in Scotland. 3 In the United States, the mortality for 
COPD doubled since 1970 to 2002 and currently ranks the fourth leading cause of death. 4 In 
Singapore, the prevalence of asthma is 10.2% in children and 11.9% in adolescents. 5 COPD 
accounts for 4.7% of all deaths and 1.2% of all hospitalizations, which is much higher than in the 
United States, Canada and other countries. 6  
 
Asthma and COPD pose significant psycho-social, economic and health care burdens to the patients, 
their families and the society. 3, 7 Notably, the concurrent poor mental health of patients with airway 
obstruction has received growing attention in recent decades, as increasing numbers of studies 8-10 
have reported that psychological factors, particularly anxiety and depressive symptoms, are even 
better predictors of obstructive airway disease-related functional impairment and quality of life (QoL) 
than lung function. Patients with severe airway obstruction experience various difficulties with 
emotional functioning, sleep and rest, physical mobility, social interaction and daily activities. 
Notably, extensive literature describes the extreme stress and anxiety provoking experience of 
dyspnea in asthma and COPD. 11, 12 During exacerbation episodes, feelings of suffocating, strangling 
or drowning are associated with heightened emotions, growing panic, extreme fear, muddled 
thoughts, and decreased physical energy. 11 The increased prevalence and severity of airway 
obstruction amidst the background of increasing mental health problems call for research into the 
relationship between stress and obstructive airway diseases. 
 
1.2 Psychiatric comorbidity in obstructive airway disease  
3 
 
Among obstructive airway diseases, asthma has historically long been considered as a typical 
psychosomatic disorder. 13 Asthma, along with other obstructive airway diseases, is associated with a 
high comorbidity with psychiatric disorders such as anxiety, depression, panic attacks, and 
posttraumatic stress disorder (PTSD). 14-16 Vazquez et al. 17 found that patients with near-fatal asthma 
showed higher psychological morbidity, notably anxiety, even years after the near-fatal asthma 
episode. Among adults with asthma and COPD, the co-occurrence of an anxiety or depressive 
disorder is associated with adverse outcomes such as poor symptom control, impaired QoL, and 
increased health care utilization. 18, 19 
 
The mechanisms underlying the psychiatric comorbidity in asthma and COPD are not well 
understood. 20, 21 It remains unclear to what extent individual psychiatric comorbidity results uniquely 
from specific or common biological responses, or from psychological factors such as environmental 
stress and poor coping which may reduce psychological dysfunction. In particular, the relative 
contribution of psychological stress to the aetiology of psychiatric comorbidities in asthma and 
COPD is not fully investigated. 
 
1.3 Psychological stress and airway obstruction 
Patients with asthma and COPD may experience various stressful life events and psychosocial 
adversities such as withdrawal from family or social life, social isolation, inability to work, 
unemployment, interpersonal problems, low self-esteem, financial loss, poor mental health, and 
reduction of social functioning and life satisfaction. With increased understanding of the 
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neurobiology of stress and the pathophysiology of airway diseases, elucidating the role of 
psychological stress in the development and control of airway obstruction is now distinctly possible.  
 
There is marked inter-individual variability in responses to psychological stress. Some individuals 
are more vulnerable, while others are more resilient. This is likely to be determined by the interaction 
of genetic and environmental factors, and the timing and duration of stress exposure. Among these 
factors, one potent determinant may be found in neuropeptides released by neurons that act as 
neuronal signalling molecules and modulate the release of neurotransmitters and hormones. 22 NPY, 
which is the most abundant neuropeptide in human brain and is involved in multiple physiological 
activities such as vasoconstriction, control of food intake and bodyweight, regulation of emotional 
response, is suggested to play an important role in explaining inter-individual variation in resilience 
to psychological stress. 23 
 
1.4. Objectives of the current study 
Stressful life events, and how it is perceived and appraised, can have extensive impact on individuals. 
The contribution of psychological stress to the psychiatric comorbidities and functioning impairment 
observed in individuals with obstructive airway diseases has not been well elucidated. Research on 
the role of NPY as a resilience factor in the inter-individual variability in responses to stress is just 
emerging. In an attempt to fill this knowledge gap, the current study aimed to assess the contribution 
of stressful life events and perceived stress in the psychiatric comorbidity and quality of life of 
asthma and COPD in adolescent, adult and elderly individuals, as well as the role of NPY in 
explaining the underlying neuroendocrine mechanism of this relationship. Accordingly, several 
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related but independent studies were conducted. For ease of reference, the studies were referred as 
Study I, Study II, Study III, Study IV and Study V respectively throughout the thesis. Study I was 
based on literature search and meta-analysis of published existing data. During the literature review, 
we found that eligible studies were mainly conducted in western countries and research in Asian 
samples was lacking. Study II-Study IV were performed to explore the stress-airway obstruction 
association and its health impact in different age groups of adolescent, adult and elderly individuals 
respectively. Finally, Study V was conducted to investigate the role of NPY in mediating stress-
airway obstruction link. 
 
We hypothesized that: 
1. Obstructive airway diseases would be associated with a high prevalence of anxiety and depressive 
symptoms and impaired QoL. 
2. More stressful exposures in the past and high concurrent levels of perceived stress might be found 
in individuals with airway obstruction compared to the healthy controls, and among poorly controlled 
patients or patients with acute exacerbations, compared to those in well-controlled or stable state. 
3. Stressful life events and perceived stress would contribute significantly towards increased 
psychiatric comorbidity and impaired QoL among individuals with airway obstruction, especially in 
poorly controlled patients and patients with acute exacerbations. 
4. Asthma would be associated with higher levels of psychological stress in young adult participants, 
corroborated by elevated levels of hypothalamo-pituitary-adrenocortical (HPA)-related levels of 
adrenocorticotrophic hormone (ACTH), noradrenaline (NA), adrenaline (A), and depressed levels of 
cortisol and NPY, reflecting blunted adaptive responses to chronic stress.    
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5. Higher levels of psychological stress (perceived stress)/biological stress (HPA index) may be 
associated with increased levels of interleukin (IL)-4, and this is likely to be mediated by the levels 
of NPY.   
 
This series of studies investigated the relationship between stress and psychiatric comorbidity in 
obstructive airway diseases among different age groups of an Asian population. These studies would 
contribute to the understanding of the role of stress in obstructive airway diseases, and provide the 
rationale for identifying key vulnerability and resilience factors for psychiatric comorbidity and 
screening patients for psychological treatment. Hopefully, the findings from this study may facilitate 
the design of future clinical trials and the establishment of a prevention and intervention framework 
for psychiatric comorbidity in asthma and COPD. Research into the role of NPY in inter-individual 
variability in stress-asthma link may enhance the understanding of psychological stress and asthma 
pathophysiology from a psycho-neuro-immunological perspective.  
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CHAPTER 2 LITERATURE REVIEW 
Obstructive airway diseases such as asthma and COPD are global public health problems which pose 
huge societal burden. As a prominent risk factor, the role of psychological stress in airway 
obstruction deserves much attention. The following literature review focuses on existing research on 
the link between stress and asthma and COPD, as well as the role of NPY as a resilience factor in the 
inter-individual variability in stress responses that is related to this thesis.  
 
2.1 Psychological stress and airway obstruction 
In previous studies, psychological stress is reported to be closely related to both asthma and COPD. 
However, the underlying mechanism remains unclear.  
 
2.1.1 Psychological stress 
Psychological stress can be defined as the non-specific psychophysiological reaction of the body to a 
variety of emotional and physical stimuli that threaten the body’s homeostasis. 24 Excessive 
psychological stress may lead to depression, psychological burnout, and PTSD in all age groups, as 
well as cognitive impairment in the elderly. 25 Stress is also a prominent risk factor for the 
development and adverse outcomes of chronic illnesses such as type 2 diabetes, coronary heart 
disease, gastroenterological disorders and obstetric outcomes. 26 
 
Psychological stress is caused by stressors and one common measure of stress is, therefore, stressful 
life events. Stressful life events contribute to anxiety and depressive symptoms and disorders. 27, 28 
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Studies found that 50%-80% of depressed persons experienced at least one major life event during 3-
6 months preceding the onset of depression, while the frequency of experience of a major life event 
evaluated at the same period was only 20%-30% in non-depressed persons. 29 Stressful life events are 
closely linked to the development of a wide range of physical diseases as well, in particular 
cardiovascular disorders, infections, autoimmune diseases, cancers, and obstructive airway diseases. 
30 
 
Although stressors are highly associated with mental and physical health problems, there are 
considerable inter-individual differences in vulnerability and resilience to potential pathogenic 
effects of stress. Stress is a subjective response composed of cognitive assessment and emotional 
reactions. According to Lazarus’s cognitive-motivational-relational theory, 31 there is a continual 
interplay between mediators such as subjective appraisals of stressful life events, coping strategies, 
and responses such as emotional reactions. Different emotions are elicited when situations are 
evaluated differently. Perceived stress, a widely used measure of the subjectivity of stress, refers to 
the feelings or thoughts that an individual has about how much stress they are under at a given point 
in time or over a given time. This measurement has been shown negatively correlated with self-rated 
health status, and self-esteem of healthy volunteers and hospital inpatients, and positively correlated 
with health complaints, anxiety and depressive symptoms, susceptibility to common cold in healthy 
adults, and emotional exhaustion. 32-36 
 
Studies suggest that individuals with certain personality traits, such as neuroticism, are more 
vulnerable to both stress and asthma than their counterparts. 37, 38 Neuroticism is a personality trait 
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manifested as the tendency to experience negative and distressing emotions, and is reportedly linked 
to psychiatric morbidity including anxiety, depression and stress susceptibility, as well as 
exacerbation of asthma. 39, 40 Prior research has suggested that neuroticism is negatively correlated 
with general health, well-being and negative perception of asthma symptoms. 37, 38 Recurrent 
unpredicted attacks of asthma, especially poorly-controlled asthma, make patients more neurotic and 
stressful; thus induce anxiety and depressive symptoms in patients with asthma. 40 
 
2.1.2 Psychological stress and asthma exacerbation 
 Asthma is an archetypal psychosomatic disease which is closely related to psychosocial or emotional 
factors, particularly stress. Historically, asthma was referred to as asthma nervosa of presumably 
psychogenic origin before the understanding of its underlying inflammatory and immunological 
mechanisms. In the 1930s and 1940s when asthma had been recognized as a chronic inflammatory 
disease, leading physicians noticed that parental stress and the quality of mother-child interaction 
could improve or exacerbate symptoms of childhood asthma. 41 Recent prospective studies reported 
that 20%-35% of patients with asthma experience asthma attack during exposure to stress. 42 A wide 
variety of psychosocial stresses, such as negative life events, certain personality types, caregiver 
stress, low socioeconomic status, and poor family relationships, have a significant impact on both 
childhood and adult asthma symptoms. 43-47 
 
Stress affects not only compliance and self-management but also the pathophysiological process of 
asthma itself. Stress caused by academic examinations promotes eosinophilic inflammation and IL-5 
production, leading to asthma exacerbations in children with mild asthma. 48 In an 18-month 
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prospective study of asthma, exposure of children to an acute negative life event (e.g., death of a 
close family member) increased the risk of asthma attack in the subsequent 4 weeks by nearly 2-fold 
(odds ratio: 1.71, 95% CI: 1.04-2.82). When acute life events occurred in the context of high chronic 
stress, the risk of asthma attack increased almost a 3-fold (odds ratio: 2.98, 95% CI: 1.20-7.38) in the 
subsequent 2 weeks. 44 Bereavement was associated with a higher risk of asthma hospitalization and 
a lower use of asthma medication in a nationwide cohort study of all singleton children (n = 
5,202,576) born in Denmark during 1977-2008 and in Sweden during 1973-2006. 49 Negative affect 
was found associated with decreases in spirometric lung function (forced expiratory volume in 1 
second (FEV1)) and increases in airway inflammation (fractional exhaled nitric oxide (FeNO)) in 
asthma patients. Both acute and chronic stress are shown to increase airway inflammation and 
proinflammatory cytokines in the airways such as IL-4. 42, 50, 51 Moreover, psychological stress is 
found to be associated with asthma that is more difficult to control, 52 with more frequent and longer 
hospitalisations, 49 with poor compliance to treatment or more psychiatric symptoms, 42 and greater 
functional impairment. 53 
 
2.1.3 Psychological stress and asthma onset  
The aetiology of asthma involves complex interactions between genetic, environmental and 
psychosocial factors. Recent studies suggest that stressful life events and perceived stress are 
associated with asthma onset. 54, 55 The first attack of asthma can be triggered by a stressful life event, 
such as death of a family member or mourning. Parental report of stress experience is prospectively 
associated with risk of wheezing among children during the first 2 years of life. 56 In a survey in 
4,010 middle-aged respondents, breaking off a life partnership predisposed to a 2.2-times higher risk 
of incident asthma 10 years later. 57 Goodwin conducted a birth cohort study of over 1,000 young 
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participants to the age of 21 years and found that childhood adversity exposure accounted for some 
of the comorbidity of asthma and depressive and anxiety disorders. 58 In a population-based cohort 
study of 16,881 participants, Lietzen et al. found that stressful life events increased the risk of asthma 
onset (HR = 1.96, 95% CI: 1.22-3.13). Moreover, this association was independent of demographic 
characteristics, smoking status, and exposure to allergens. 59 Except for acute stressful experience 
triggered asthma onset, studies found that chronic stress such as inadequate parental support and 
chronic caregiver stress were also associated with asthma exacerbation and the development of 
allergic diseases. 60 In a systematic review and meta-analysis, Chida et al. reported a positive 
association between chronic psychological stress and the presence of future atopic disorders 
including asthma. 61 This suggests that stress may play a prominent role in the development and 
continuation of asthma. 62 
 
In a 10-year longitudinal study of 5648 individuals without asthma or allergic rhinitis at baseline, 55 
perceived stress was associated with a higher risk of self-reported asthma incidence, daily intake of 
asthma medication, and first-time asthma-caused hospitalization in a dose-dependent manner. This 
association was independent of participants’ sociodemographics, history of parental asthma, smoking 
status, and lung function at baseline. In summary, chronic stress may accelerate, and acute stress may 
trigger, the onset of asthma. The impact of stressful life events varies subjectively due to the 
considerable variability in perceived stress which is determined by people’s cognitive assessment, 
and emotional and physiological responses to stress. 63 It is therefore essential to assess both stressful 
life events and the inter-individual variance of subjective perception (perceived stress) in the 




2.1.4 Psychological stress and COPD 
High levels of stressful life events and perceived stress are reported in patients with COPD. 64 
Moreover, psychological stress is a predictor of adverse health effects, a high risk of relapse or 
readmission after emergency treatment, and high use of community health care resources in COPD. 
64-66 Among patients with COPD, an intrinsic source of stress is directly related to their illness, 
involving the experience of anxiety and stress provoked by breathing difficulties, including muddled 
thoughts, heightened emotions, extreme fear and panic and decreased physical energy, and various 
difficulties in emotional functioning, sleep and rest, physical mobility, social interaction, daily 
activities, recreation, work and finance. 67-69 Emotional arousal, of either positive or negative affect, 
triggers dyspnea in patients with COPD. 70 Stress level remained high over time in COPD patients 
even after discharge from hospital, suggesting a persistent high level of stress experienced by patients 
during both acute and stable phases of the illness. 71, 72 Gueli et al. found that perceived stress 
contributed to lung inflammation, as manifested by the significantly higher leukotriene B4 (LTB4), 
IL-8 and tumor necrosis factor alpha (TNF-α) levels, in patients with stable COPD. 73  
 
2.1.5 Underlying mechanism 
Although hypothesized to be a complex neuroendocrine-immune system interaction 74 in which the 
HPA axis plays a major role, the underlying mechanism of the stress-airway obstruction association 
is complex and has not been well elucidated.  
 
A hypothesis of stress-induced inflammation was proposed based on study findings that 
psychological stress exacerbates symptoms of inflammatory disorders such as asthma, rheumatoid 
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arthritis and inflammatory bowel disease. 43, 75, 76 The inflammatory activity is regulated by the 
central and peripheral nervous systems, and related neurotransmitters. Stress may activate the HPA 
axis and the sympathetic nervous system, leading to release of cortisol and catecholamines that 
influence cell trafficking, proliferation and function, and cytokine and inflammatory mediator 
production. Neural responses to stress promote inflammation, and increases in inflammation in turn 
enhance neural sensitivity to stress. This suggests a bidirectional communication between neural 
systems and inflammatory process in which stress-related neural activity and inflammation may be 
mutually promoting and, over time, form a recursive loop that increases both levels of inflammation 
and risk of psychiatric symptoms. 77, 78 
 
Duration of stress exposure appears to be an important modulator of stress, and different effects of 
acute versus chronic stress on the immune system have been reported. Acute stress activates the HPA 
axis, leading to consequent cortisol release and reduction of airway inflammation; while continuous 
prolonged or intermittent stimulation, as in chronic stress, dampens HPA axis responsiveness and its 
anti-inflammatory effect. 42, 79 This is corroborated by clinical studies in which asthma patients who 
are not treated with inhaled corticosteroids (ICS) are likely to experience an attenuated activity 
and/or responsiveness of the HPA axis. In line with this concept, most asthmatic children 
demonstrate improved HPA axis responsiveness on conventional doses of ICS, as their airway 
inflammation subsides. 80, 81 
 
It is well-known that stress response shows marked inter-individual variability which is likely to be 
determined by genetic, biological and environmental factors, and as indicated above the timing of 
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stress exposure. A strong determinant of such inter-individual differences in stress response may be 
found in neuropeptides released by neurons that act as neuronal signalling molecules and modulate 
the release of neurotransmitters and hormones. 22 
 
2.2 Inter-individual variability of stress and asthma 
Because asthma often has its origins in early life, childhood asthma has received widely attention in 
research. However, asthma is a chronic respiratory disease affecting all age groups, though with 
distinct age characteristics and significant inter-individual variability. Individualized treatment 
regimens for asthma need to be established according to the characteristics of patients depending on 
their ages and inter-individual differences. 
 
2.2.1 Age characteristics of asthma 
As a leading cause of disease burden, asthma affects individuals across the entire age spectrum from 
infants to the elderly. With the increase of age, the predominance of boys in childhood among 
individuals with asthma gradually diminishes until puberty when a higher incidence of new cases of 
asthma is observed in girls, and adult asthma affects more women than men. 82 Childhood asthma is 
among the most common chronic paediatric medical disorders which shows relatively high 
frequencies of EMD visits, prolonged hospitalizations, and low mortality. 83 Moreover, the clinical 
severity of asthma in childhood is reported to be a risk factor for the persistence and severity of 
asthma in adulthood. 84 Psychological factors play an important role in the exacerbation and 
treatment of childhood asthma. Miller et al. 85 reported that children who died from asthma 
experienced a recent or impending separation or loss and had high levels of hopelessness and despair 
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in the days preceding their deaths. In a small-scale study, psychological intervention including 
relaxation, cognitive stress management, and a self-esteem workshop improved FEV1 and decreased 
specific immunoglobulin E (IgE) response in asthmatic children. 86 However, young children may 
have difficulty in reporting their psychological status accurately and consistently. Parental assistance 
generally exaggerates the physical and psychological symptoms children experience and causes 
potential bias. 87 Therefore, young children are often excluded from psychological studies which rely 
on self-reports of emotions. 
 
Adolescents are in a period of remarkable physical, psychological and personality development, 
which is filled with rapid changes, roles adaptation and feelings of self-doubt. Hence, they are 
vulnerable to the negative impact of asthma. 88 Adolescent asthma is relatively dynamic with 1 in 5 
young children with asthma remit but may subsequently relapse after a symptom-free interval. 89 
Patients in this age group usually underestimate the severity of their disease and denial of symptoms 
is characteristic of adolescents with asthma. They are usually not willing to take asthma medication 
in front of their peers and have poor adherence to prescribed treatment regimens. The under-
estimation and inadequate treatment of asthma symptoms often induce poor outcome of asthma in 
adolescence. Studies showed that it is more common among adolescents than younger children to 
experience asthma exacerbations requiring hospitalization, intubation, and cardiopulmonary 
resuscitation and fatal outcomes. 90 In a study conducted in Dutch, 27% of adolescents with asthma 
believed that their asthma symptoms were provoked by prolonged emotional arousal or stress, and 
40% of the participants linked their symptoms to sudden anger or sadness. 91 Compared with their 
healthy counterparts, adolescent asthma patients exhibit higher levels of anxiety and depression, 
increased suicidal ideation and lower self-esteem. 92, 93 The severity of psychiatric comorbidity is 
16 
 
correlated to the severity of asthma symptoms, impaired functioning and poor adherence to treatment 
regimens. 94, 95 
 
Adult asthma, with approximately 60% persisting from childhood and 40% adult-onset, is relatively 
stable compared with other age groups. 96, 97 Adult-onset asthma is mainly non-atopic and affects 
predominately females. It is frequently associated with a variety of specific triggers such as smoking, 
respiratory tract infections, aspirin intake, exposure to occupational agents, and obesity. Most 
patients with adult-onset asthma have mild transient disease, whereas others exhibit a progressive 
course with high exacerbation rate and rapid loss of lung function. 98, 99 The increased prevalence of 
asthma morbidity and mortality has been linked to excessive stress and emotional strains in modern 
life. 100 Levitan reported six adults whose symptoms of asthma began during periods of intense 
mourning. 101 Among them, four patients reportedly manifested asthma 1 week to 3 months after the 
death of a relative, and the other two patients on the day of the death or funeral. Rumbak et al. found 
that a majority of the subjects with asthma responded the "frequently" or "always" category when 
asked how often asthma attacks were preceded by their being upset or anxious. 102 Watching stressful 
films increase airway obstruction in adults with mild asthma. 103 In population-based studies, 
stressful life events were associated with an increased risk of hospital admissions due to asthma. 104 
There may be a vicious circle of bidirectional interaction between asthma and stress which affects the 
management of asthma and patients' quality of life.  
 
In the elderly, the diagnosis of asthma is often difficult due to greater irreversibility of airflow 
obstruction, comorbidities with COPD and other chronic medical conditions, and the advancement of 
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age, leading to under-diagnosis and under-treatment of asthma in the elderly population. 105, 106 
Compared with younger age groups, older individuals with asthma tend to have lower incomes, less 
formal education, higher requirement for systemic corticosteroid therapy, shorter symptom-free 
periods, and more daily activity limitation because of asthma. 107-109 While higher asthma prevalence 
is observed among younger age groups, elderly individuals with asthma have worse control of 
asthma and a higher mortality than other age groups. 110 In the United States, over 50% of asthma-
related deaths annually occur in asthma patients aged 65 years and above. 111 Although asthma is not 
considered a common direct cause of death among the elderly, the co-existence of asthma and other 
risk factors, such as smoking, cardiovascular disease, and psychological symptoms, may exert a 
heavy burden on health care utilization and partially account for the excess fatalities. 111, 112 
Consistent with the clinical criteria of diagnosing airflow obstruction, 113 this study employed an 
objective parameter of chronic airflow obstruction defined as post-bronchodilator FEV1/forced vital 
capacity (FVC) < 0.70 in order to avoid the confounding of the non-specific symptoms and signs of 
airway disease in the elderly. Important demographic and disease-related variables including sex, age, 
ethnicity, smoking status, and number of medical comorbidities were adjusted in the statistical 
analyses in the elderly population. 
 
2.2.2 Inter-individual variability of stress 
The relationship between stress exposure and psychopathology is extremely complicated. It can be 
illustrated by considering not only stress exposure but also the vulnerability and resilience of the 
individual who is exposed to stressors. It is well-known that there is marked inter-individual 
variability in responses to stress. Some individuals are more vulnerable, while others are more 
resilient. Many individuals who are exposed to similar levels of adversity with those having PTSD do 
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not develop psychopathology or are able to recover quickly. This is determined by a variety of 
genetic, neurobiological, environmental, and psychological factors. 114 
 
The neurobiological responses to stress involve the central nervous system, peripheral nervous 
system, related neural circuits and neurotransmitters, neuropeptides, and hormones, in particular the 
HPA axis. 115 The central control stations of stress response are located in the hypothalamus and the 
brain stem. When confronted with a stressful situation, activation of the HPA axis initiates the 
production of corticotropin-releasing hormone (CRH), stimulates the secretion of ACTH from the 
anterior pituitary, and finally activates the secretion of corticoids by the adrenal cortex. In the 
meanwhile, the coeruleus activates the sympathetic nervous system, and releases adrenaline and 
noradrenaline at the sympathetic nerve endings. The released catecholamines and corticoids suppress 
Th1 cell response such as the production of IL-12 and promote the Th2 cell production such as IL-4, 
IL-10 and IL-13. This results in a Th1/Th2 imbalance in favor of Th2 cell mediated response, with 
dysregulation of the neuroimmunologic homeostatic mechanisms secondary to chronic stress, which 
ultimately affects cytokine expression and favours an allergic inflammatory response such as asthma. 
116 
 
There are a number of key neuroendocrine mediators involved in the neurochemical response 
patterns to stress, such as cortisol, CRH, ACTH, noradrenaline, and so on. Evidence has 
demonstrated that psychological stress increases the synthesis and release of cortisol which 
replenishes energy stores, contributes to increased vigilance, and inhibits the growth and 
reproductive system and the immune response. 117 CRH coordinates stress-related adaptive 
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behavioural and physiological changes. During stress, release of CRH activates the responsiveness of 
the HPA axis and increases cortisol and dehydroepiandrosterone (DHEA) secretion. The activity of 
the CRH neurons is associated with the activation of fear-related behaviours, reduction of reward 
expectation, and inhibition of a variety of neurovegetative functions such as food intake, sexual 
activity, and endocrine programs for growth and reproduction. 118 ACTH, secreted by the anterior 
lobe of the pituitary gland into the body’s blood stream, stimulates the cortex of the adrenal gland by 
binding to its ACTH-receptors and promotes the release of cortisol from the adrenal gland. As a 
stress hormone, noradrenaline affects brain regions that are responsible for attention and responding 
to actions. Noradrenaline and adrenaline form the basis for the fight-or-flight response by directly 
increasing heart rate, stimulating glucose release from stored energy, and enhancing blood supply to 
skeletal muscles. 23 
 
In 1982, Tatemoto and Mutt 119 extracted NPY from porcine brain. Accumulating evidence suggests 
that, under physiological conditions, NPY functions as an endogenous anxiolytic agent that buffers 
against the effects of stress on the mammalian brain. 120 The role of NPY in stress resilience as a 
major neurotransmitter remains to be fully elucidated. 
 
2.3 Neuropeptide Y and inter-individual variability in stress-asthma link 
NPY is a peptide which has widespread central and peripheral distribution and multiplephysiological 
effects. As a neuropeptide, the anxiolytic effect of NPY via the amygdala has received growing 
attention. Psycho-neuro-immunological studies on the role of NPY as a resilience factor in 
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interpreting the inter-individual variability of stress help to illuminate neurotransmitter imbalances 
and dysfunctions involved in response to psychological stress. 121 
 
2.3.1 Structure and function of Neuropeptide Y 
NPY is a highly conserved 36-amino acid peptide neurotransmitter found in the arcuate nucleus of 
the hypothalamus. It is one of the most abundant peptides in the central nervous system of mammals 
and regulates multiple physiological activities. 122 In the endoplasmic reticulum, NPY is synthesized 
as a large precursor protein. Once synthesized, NPY moves to the Golgi apparatus, and is then 
translocated into the trans-Golgi network (TGN) where the peptide is stored until further activation. 
123 NPY is most abundant in the neurons of five brain areas including the locus coeruleus, the 
paraventricular nucleus of the hypothalamus, septohippocampal neurons, the nucleus of the solitary 
tract, and the ventral lateral medulla. Moderate levels of NPY are found in the amygdala, 
hippocampus, cerebral cortex, basal ganglia, and thalamus. 124 At these brain areas, NPY is shown to 
have two major functions: stimulating food intake and modulating stress response. Injection of NPY 
into the paraventricular nucleus stimulates strong feeding-stimulatory responses; 125 while injection 
of NPY into the paraventricular nucleus triggers the secretion of ACTH which initiates a cascade of 
stress-related events and results in the release of cortisol. 126  
 
In the periphery, NPY is mainly found in sympathetic nerves, the adrenal medulla, and platelets. 
Studies have shown the co-release of NPY, noradrenaline, and Adenosine Triphosphate (ATP) from 
axon terminals under isolated, in situ and in vivo stimulation of organs by sympathetic activation. 127, 
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128 Clinically, elevated plasma NPY levels are observed in diseases with increased sympathetic 
outflow such as hypertension, 129 chronic heart failure, 130 and renal failure. 131 
 
In animals, NPY is found to subserve functions in regulating behaviour and adaptation of the 
organism during environmental challenges such as starvation, infection and predator attack. 132, 133 
Human studies found that NPY is involved in the regulation of several basic physiological functions 
and disorders such as the control of anxiety, seizures, memory, circadian rhythm, food intake, 
metabolic disorders, drug addiction, pain, cardiovascular diseases, rhinitis, and endothelial cell 
dysfunctions, through the activation of six G-protein-coupled receptor subtypes named Y1, Y2, Y3, 
Y4, Y5, and Y6. 123 NPY co-exists with stress hormones adrenaline and noradrenaline in neurons of 
the nucleus of the solitary tract and the autonomic nervous system, augments the vasoconstrictor 
effects of noradrenergic neurons, and regulates the release of many neurotransmitters including 
adrenaline and noradrenaline. 
 
2.3.2 Neuropeptide Y and psychological stress 
There is interplay between the NPY system and the classical HPA axis and the sympathetic-
adrenomedullary (SAM) axis stress response systems both centrally and peripherally. Exposure to an 
acute stress leads to the expression and release of NPY in multiple stress-sensitive areas of the brain. 
134 The negative feedbacks of NPY-ergic activity, which is in anxiolytic fashion on CRH, may be 
regarded as “anti-stress”. 120 On the other hand, glucocorticoids are capable of modulating the 
expression of NPY messenger ribonucleic acid (mRNA) in the arcuate nucleus, thus exacerbating the 
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response to stress. 135 Meanwhile, similar interactions between glucocorticoids and NPY are also 
observed in the periphery. 136  
 
High NPY levels are associated with better performance in soldiers of special operations under acute 
and extreme training stress, but chronic stress seen in long-term patients with PTSD is shown to 
reduce plasma NPY levels. 137, 138 Low levels of NPY are also found in depressed patients, and a 
variety of antidepressant drugs increase NPY levels. The balance between NPY and CRH 
neurotransmission is therefore important to the long term emotional responses to stress and reduction 
of the allostatic load. Although evidence is not extensive, these studies indicate the possibility of 
NPY playing a key role in triggering and propagating the stress response. 
 
2.3.3 Neuropeptide Y and inter-individual variability of stress in asthma  
Evolutionarily, the function of NPY appears to be under conditions of cold climate and in situations 
where food is sparse, as the peptide stimulates coping and food-seeking behaviour, and regulates 
cardiovascular, neuro-endocrine and immune adaptations. 135 Under stress, NPY exerts a major 
influence on humoral and cellular immune functions, which are intimately involved in asthma 
pathophysiology. NPY modulates potent immunological effects such as immune cell distribution, T 
helper cell differentiation, mediator release, and natural killer cell activation. 139 
 
NPY exists not only in neurons, but as well in neuroendocrine and inflammatory cells in the lung. 
Exposure to stressful life events may result in the release of NPY in the airways and peripheral 
23 
 
circulation during asthma exacerbations. 139 There are a few studies investigating the role of NPY in 
asthma in prior research. Dahlof et al. found elevated plasma concentration of NPY and low level of 
circulating adrenaline in elderly asthmatics during rest and acute severe asthma compared with the 
healthy controls. Cardell et al. reported that during an exacerbation of asthma, patients displayed low 
plasma concentrations of NPY and elevated levels of other neuropeptides. Doniec et al. examined the 
serum level of NPY (and leptin) in children with mild asthma and observed no difference of NPY 
levels between the asthmatics and the healthy children. 140-142 Macia et al. in 2011 found that NPY 
exacerbates allergic airway inflammation (AAI) in mice via its Y1 receptor which is closely related 
to stress. 143 Aldrich et al. reported that Puerto Ricans exhibit a significant association between single 
nucleotide polymorphism (SNP) rs5574 and asthma prevalence (OR = 1.28, 95% CI: 1.02-1.60). 
Two SNPs, rs16143 and rs5574, are associated with severe asthma (OR = 1.48, 95% CI: 1.11-1.96 
and OR = 1.44, 95% CI: 1.09-1.89, respectively). However, among Mexicans, associations of asthma 
and NPY variants are not statistically significant. 144 The association of stress and asthma suggested 
by these preliminary studies deserves further investigation. 
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CHAPTER 3 METHODS 
3.1 Study I: Prevalence of anxiety and depressive symptoms in adolescents with asthma: a 
meta-analysis and meta-regression 
3.1.1 Search strategy 
An extensive literature search was performed using the keywords “depress*”, “anxiety”, “psych*”, 
“behaviour”, “paediatric”, “children”, “adolescent”, “youth”, and “asthma”,  to retrieve case-control 
studies published in multiple computerized databases: PubMed (from 1966 to Nov 2011), Embase 
(from 1980 to Nov 2011), BIOSIS (from 1926 to Nov 2011), PsychINFO (from 1806 to Nov 2011), 
Science Direct (from 2006 to Nov 2011) and Cochrane CENTRAL (from 1993 to Nov 2011). 
Relevant articles were also searched from the bibliographies of the retrieved original studies and 
review articles. We contacted the corresponding authors for any information lacking in their 
published articles to calculate the effect size.  
 
3.1.2 Criteria for article selection 
Observational case-control studies addressing the difference in depressive and/or anxiety symptoms 
between adolescents with asthma and the healthy controls were included in this meta-analysis if they 
met the following criteria: 1) conduction of human studies involving adolescents (aged 13-18 years) 
grouped by asthma and the healthy controls; 2) identification of clinically relevant depressive and/or 
anxiety symptoms; 3) written in English; 4) having a total sample size of no less than 50 subjects. We 
included both cross-sectional and the first round data collection of prospective studies. Two 
investigators (YL and RCMH) independently assessed the relevancy of the manuscripts and 
ineligible manuscripts were excluded according to the following exclusion criteria: 1) comparisons 
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between asthma patients and the healthy controls were not available; (2) a standardized effect size 
could not be calculated. Approval from an institutional review board was not required because this 
meta-analysis mainly involved data from published studies.  
 
3.1.3 Data abstraction 
All articles were first de-identified (blinded title, author(s), journal name and year of publication) 
before selection. Two investigators (YL and RCMH) independently reviewed the abstracts of the 
studies and extracted relevant data from eligible papers into standard electronic forms. Any 
discrepancies were resolved by consensus. If consensus could not be reached, the principal 
investigators (RCMH) would make the final decision for study eligibility and data extraction. 
   
3.1.4 Statistical analyses 
All statistical analyses in this meta-analysis were performed using the Comprehensive Meta-analysis 
Programme, Version 2 (Biostat, Englewood, NJ, USA). Random effects meta-analysis was 
performed as suggested by DerSimonian and Laird 145 to test whether the aggregate prevalence of 
depressive and anxiety symptoms was the same in these two groups. The forest plots were prepared 
using R. 146 
 
As the number of studies included in this meta-analysis is relatively small, the Cochran Q-test for 
heterogeneity may yield a low statistical power. 147 A value of significance at 10% (p ≤ 0.1) was 
therefore considered statistically significant for heterogeneity. 148 Meanwhile heterogeneity was 
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assessed with I2, which is defined as the percentage of total variation of all studies caused by 
heterogeneity rather than change. High values of I2 suggest increased heterogeneity. Publication bias 
was evaluated with Egger's test in our analysis. 
 
For models with considerable heterogeneity and statistically significant effect size, meta-regression 
was performed to identify demographic and disease-related factors (age, gender, ethnicity, smoking 
status and severity of asthma) that might contribute to the heterogeneity. 149 Since the chosen 
covariates were not expected to explain all the heterogeneity of the studies, mixed-model meta-
regression was used in consideration of the presence of “residual heterogeneity”. 149 The regression 
coefficients and the associated standard error (SE), the z score, degree of freedom (df), and p values 
were reported for the meta-regression analysis.  
 
3.2 Study II: Asthma control, perceived stress, and quality of life in adolescents with asthma: a 
case-control study 
3.2.1 Study design and participants 
This is a clinical study with a cross-sectional design. Adolescents (aged 12-19 years) with asthma 
diagnosed by a paediatrician (HPVB) were recruited from April 2011 to June 2012, including 137 
patients with well-controlled asthma and 61 with poorly controlled asthma from the specialist clinics 
and wards of Department of Paediatrics, National University Hospital (NUH). A group of 171 
healthy controls were neighbourhood volunteers age-matched (+/-2 years) and gender-matched with 
asthma patients, without current or previous history of asthma. Adolescents with other chronic 
diseases, especially any other pulmonary disease (cystic fibrosis, etc.), mental incapacitation or 
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learning disability, with difficulty understanding and responding to questions were not eligible for 
this study. All participants and their parents signed written informed consent for the study which was 
approved by the National Healthcare Group Domain Specific Review Board (DSRB). The response 
rate was 92%. Self-administered questionnaires were completed in English by the respondents who 
were multi-ethnic but received a common education in English as first language. 
 
3.2.2 Asthma control and asthma quality of life 
The degree of asthma control was determined using the Asthma Control Test (ACT), a widely-used 
self-administered questionnaire in clinical and research settings for the assessment of asthma with 
strong evaluative and discriminative properties in general 150 and locally 151. Participants responded 
to 5 questions pertaining to episodes of dyspnea, sleep impairment due to asthma symptoms, 
limitations in daily activities, the use of rescue inhalatory medications, and self-rated degree of 
asthma control in the past four weeks. Participants responded to a 5-point Likert scale. A score of 20 
points or higher corresponded to well-controlled asthma and equal to or less than 19 suggested poorly 
controlled asthma.  
 
The impact of asthma on children's quality of life was assessed by the Paediatric Asthma Quality of 
Life Questionnaire (PAQLQ), which has been extensively tested for reliability and validity in 
multiple populations 152 including Singaporeans 153. The questionnaire includes 23 items in 3 
domains: activity limitations (5 items), symptoms (10 items), and emotional function (8 items). 
Questions are regarding how bothered in the past week children were by cough, wheeze, tightness of 
the chest and shortness of breath, and asthma attacks, limitation with physical activities, exposure to 
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animals, and activities with friends and family, etc.. Response options for the questions were 7-point 
Likert scales ranging from “extremely bothered” to “not bothered” or “all of the time” to “none of the 
time”. A lower PAQLQ score indicates impaired quality of life. 
 
3.2.3 Depression and anxiety 
Revised Child Anxiety and Depression Scale (RCADS) is a 47-item self-administered questionnaire 
for screening a broad range of Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-Ⅳ) anxiety and depressive disorder symptoms in adolescents and young children, 154 
with scales corresponding to panic disorder, social phobia, generalized anxiety disorder (GAD), 
obsessive compulsive disorder, separation anxiety disorder, and major depressive disorder (MDD). 
The questionnaire also derives scores on Total Anxiety Scale (sum of the 5 anxiety subscales) and 
Total Internalizing Scale (sum of all the 6 subscales). Respondents are required to rate how often 
each item applies to them on 4-point Likert scales with the options of “never,” “sometimes,” “often,” 
and “always”. Raw scores are transformed into standard T scores based on subjects’ gender and 
grade levels. T scores of 65 or higher indicate that the subject is at the borderline clinical threshold of 
anxiety or depressive disorders. T scores of 70 or higher are above the clinical threshold of 
psychiatric morbidity. RCADS has shown excellent psychometric properties and robust construct 
validity 154 in cross-validation studies including in Asian countries and is available in multiple 
languages. 154 
 
3.2.4 Stressful life events and perceived stress 
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The Holmes-Rahe Social Readjustment Ratings Scale 155 (SRRS, for children) is used to measure the 
number of significant stressful life events experienced by participants in the past one year. The scale 
examines stressful life events that necessitated life-style changes requiring social readjustment. 
Stressful life events listed on the SRRS pertain to significant areas in the social structure of daily life, 
including marriage, pregnancy, education, occupation, family, group and peer relationships, 
economic concerns, religion, recreation, and health. This scale has been validated cross-culturally for 
Asian populations. 156, 157 
  
Perceived Stress Scale (PSS) is a widely used psychological instrument for the measurement of 
perception of stress and has been validated in many studies 158 and in Singaporean samples 159. It 
measures the degree to which situations in one’s life is appraised as stressful. Items are designed to 
detect how unpredictable, uncontrollable, and overloaded respondents find their lives over the past 
month. All items begin with the phrase: In the past month, how often have you felt…? The questions 
are of a general nature and hence are not directed at any particular sub-population group. The scale 
derives a perceived stress score that ranged from 0 to 40 with a higher score indicating experience of 
greater stress. High PSS scores were shown to be associated with poor self-reported health status and 
vulnerability to depressive symptoms. 160  
 
3.2.5 Socio-demographic data and self-rated health 
We measured socio-demographic variables such as gender, age, ethnicity (Chinese, Malay, Indian or 
others), smoking status (non-smoker, past or current smoker), family housing type as a proxy for 
socioeconomic status (1-2 room public, 3 room public, 4-5 room public, private or landed house), 
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and Body Mass Index (BMI). 
 
Self-rated health (SRH) was assessed with one item “Would you say that in general your health 
is…?” Participants were asked to answer with a 5-category Likert response scale (excellent, very 
good, good, fair or poor). Self-rated health is a widely used measure of general health and has been 
shown to predict subsequent mortality and morbidity in both population and clinical samples, even 
after accounting for socio-demographic and other health-related characteristics. 161, 162  
 
3.2.6 Statistical analyses 
Data analysis was performed using Predictive Analytics Software (PASW) Statistics version 18. 
Differences in socio-demographic status, measures of psychiatric comorbidity, underlying 
psychological factors and their correlates, and QoL were investigated among groups with poorly 
controlled asthma, well controlled asthma versus the healthy controls, using 2-tailed Chi-squared test 
and One-way Analyses of Variance (ANOVA), with pairwise comparisons between groups using 
Bonferroni adjusted p values. Pearson correlational analysis was used to examine the relationship 
between asthma, psychological and psychiatric variables. The scores of psychiatric comorbidity were 
compared among the three groups in generalized linear regression models, controlling for potential 
confounders (gender, age, ethnicity, smoking status and family housing type). To evaluate the role of 
perceived stress in mediating the observed difference in psychiatric comorbidities among the 
participants, we included the variable in the prediction model of psychiatric comorbidities, together 
with diagnostic checks for multi-collinearity. The change in the strength of association, the level of 




3.3 Study III: Asthma, psychological stress and psychiatric comorbidity: a population-based 
study in adult Singaporeans 
3.3.1 Study design and participants 
This study used cross-sectional data from a national stratified random population sample (n = 2847) 
in the National Mental Health Survey (Adults) (NMHS (A)) of Singapore, conducted from 15 
February 2003 to 30 March 2004. The random sample list was generated by the Department of 
Statistics using pure probability sampling from a national sampling frame based on population census 
of persons residing in coded districts throughout the country. The NMHS (A) used an ethnically 
stratified random sample of households to identify eligible adults aged 20-59 years who were 
Singapore citizens or permanent residents. One eligible person per household was invited to 
participate in the survey. A total of 2,847 individuals were interviewed from 3,875 randomly selected 
eligible persons, with a response rate of 75.2%. A multi-language team of trained field interviewers 
performed face-to-face questionnaire interviews at the subjects’ home. The interviews were 
conducted in the language or dialect with which the subjects were most conversant: English, 
Mandarin or other Chinese dialects, and Malay. Participants gave written informed consent for the 
study which was approved by the Ethics Committee of the Institute of Mental Health. 
 
3.3.2 Asthma and other chronic physical conditions 
The presence of asthma was ascertained by subjects’ self-reports of a doctor’s diagnosis of asthma: 
“In the past 12 months, have you been told by a doctor, nurse, or other health professional that you 
had asthma?” (“yes”, “no”), and “Do you still have asthma?” (“yes”, “no”). Self-reports of asthma 
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diagnosis based on these two questions are shown high reliability and validity in multiple population 
surveys of asthma prevalence. 163-167 Additionally, the respondents were asked to show their 
medication packages, and were considered to have asthma when the use of appropriate asthma 
medications was verified by the interviewer. Additional questions for those with a positive response 
of asthma diagnosis included their duration of asthma, frequency of doctor visits and hospitalizations 
for asthma exacerbations.   
 
In the meanwhile, the subjects were asked whether in the 12 months prior to interview they had been 
diagnosed and treated by their doctors for any of 14 other chronic physical illnesses (“yes”, “no”), 
which included coronary heart disease, heart failure, hypertension, lipid abnormalities, diabetes, 
stroke, cancer, hip fracture, arthritis, chronic obstructive pulmonary disease, cataract, kidney failure, 
urinary disorders, and “other specified conditions”. The self-reported diagnoses of physical illnesses 
were corroborated by information provided on the use of appropriate medications as verified by the 
interviewer, and duration of illnesses, frequencies of doctor visits and hospitalization in the last 12 
months.  Two respondents who reported both chronic obstructive pulmonary disease and asthma were 
classified among the 144 respondents who had asthma. The number of chronic physical illnesses was 
calculated for each individual, and the sum score of number of coexisting physical illnesses except 
the index illness was used as a covariate in the statistical analysis.    
 
Based on information on physical medical conditions provided, individuals were categorized in three 
groups of study participants: asthma (A), other chronic physical conditions (B) and no chronic 
physical conditions (C). Thirty-eight individuals having both asthma and other chronic physical 
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conditions were excluded from the asthma group and in the analysis. 
 
3.3.3 Psychiatric disorders 
Diagnosis of psychiatric disorders was made using a two-stage case ascertainment procedure, in 
which participants were first screened using the General Health Questionnaire (GHQ)-12, and 
screen-positive individuals (GHQ ≥ 2) underwent diagnostic interviews for psychiatric disorders 
including MDD, GAD and others using the Schedule for Clinical Assessment in Neuropsychiatry 
(SCAN). 
 
The GHQ-12 168 is widely used by researchers and clinicians as a screening instrument to detect 
psychiatric disorders in community settings and non-psychiatric clinical settings. 168 The 
questionnaire has demonstrated stable discriminating power cross-culturally 169 in 11 translated 
versions, and its validity has been documented in previous studies in Singapore. 170, 171 A 
recommended cutoff score of 2 172, 173 denotes psychological disturbance. Among respondents with 
GHQ scores of at least 2 who underwent further diagnostic interview using the SCAN, 174 the 
positive predictive value was 31%. In validation studies, a random one-in-ten of the subjects with 
GHQ-12 scores below 2 were also further interviewed using the SCAN to address false-negative 
results from screen-negative respondents, and the GHQ-12 gave a sensitivity of 92.1% and 
specificity of 48.1% for depression/anxiety. 175 
 
Interview data generated from SCAN (created by World Health Organization) were used to make 
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case diagnoses of psychiatric disorders including MDD, GAD and others in the previous 12 months 
period in accordance with DSM-Ⅳ 176  criteria. SCAN has been found to be generally acceptable, 
appropriate and reliable across cultures and settings 177 when administered by trained lay interviewers 
in community surveys. 178, 179 Case diagnoses of psychiatric disorders including any psychiatric 
disorder, MDD and GAD were evaluated as dichotomous variables (0 = no, 1 = yes) in the statistical 
analysis. The multi-ethnic interviewers were experienced psychiatric nurses from the Institute of 
Mental Health who were trained in the use of the SCAN by a senior psychiatrist who had received 
training from a WHO training centre. To ensure the conduct of interviews in accordance with the 
study protocol and accuracy of diagnoses, quality checks was conducted through weekly on-site 
supervision and cross-checking of interview response data by the research coordinator and 
psychiatrists.  
 
3.3.4 Stressful life events and quality of life 
Subjects were asked whether they had experienced any stressful life events in the previous 6 months 
from a List of Threatening Experiences Questionnaire (LTEQ). 180 The LTEQ consists of 12 items of 
stressful life events, including serious illness or injury to self or close relative, death of parent or 
spouse or child, etc.. A total number of reported stressful life events, as well as in each type (threat, 
loss or mixed) was computed for each subject. Missing values for items were given null values for a 
small number (< 5%) of items and study participants. 
 
Health-related quality of life was measured using the Medical Outcomes Study 12-item Short Form 
(SF-12) which has been widely used in clinical and large population health surveys including 
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samples of Singaporean adults. 181-183 Scores are computed on two scales of mental and physical 
functioning, Physical Component Summary (PCS) and Mental Component Summary (MCS), using 
the weighted scores of all twelve questions. The possible scores range from 0 to 100, where zero 
indicates the lowest level of health functioning measured by the scales and 100 indicates the highest 
level of health functioning.  
 
3.3.5 Statistical analyses 
Differences in socio-demographic factors, any psychiatric disorder, MDD and GAD, and number and 
type of stressful life events were evaluated among the three study groups using 2-tailed Chi-squared 
test. Crude and adjusted odds ratio (OR) of association of psychiatric disorders (any psychiatric 
disorder, MDD and GAD) with asthma versus no chronic physical conditions (A versus C), other 
chronic physical conditions versus no chronic physical conditions (B versus C), and asthma versus 
other chronic physical conditions (A versus B) were estimated in univariate and multivariable logistic 
regressions. To control for potential confounding, the latter included as covariates sex, age, ethnicity, 
employment status, marital status, highest education, and number of coexisting chronic illness, 
determined a priori to be known important risk factors for psychiatric disorders or morbidity. 
 
To measure the role of stressful life events in mediating the association of coexisting psychiatric 
disorders with asthma and other chronic physical conditions, the author evaluated the change in the 
magnitude of ORs in hierarchical models by including number of stressful life events in the model 
and observing the decrease (to non-significant value or zero) in the OR of association between 
asthma (or other chronic medical conditions) and psychiatric disorder. 184 Sobel test was used to 
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evaluate the statistical significance of the mediation. Reported p-values were obtained from the unit 
normal distribution under the assumption of a two-tailed test. 
 
The mean level of SF-12 MCS measure of QoL was compared among the groups with asthma, other 
chronic physical conditions and without chronic physical conditions. Potential confounders were 
adjusted in analyses of covariance using generalized linear regression models. We added separately 
in the model number of stressful life events, any psychiatric disorder, MDD and GAD in order to 
compare their relative contributions in explaining the observed differences in QoL. 
 
3.4 Study IV: The impact of stressful life events on quality of life in the elderly with airway 
obstruction 
3.4.1 Study design and participants 
The participants in the study were a subsample (n = 497) recruited from one locality (Bukit Merah) in 
the South Central region of Singapore Longitudinal Ageing Study (SLAS)-2 which is a prospective 
population-based cohort study of aging and health of community-dwelling elderly. 185 Trained 
research nurses interviewed one participant from each household who were Singaporean citizens or 
permanent residents aged 65 or older and were able to give informed consent. Those who were too 
frail or ill and unable to complete the interview, for reasons such as from post-stroke aphasia, 
cachexia or profound dementia, were excluded. All participants signed written informed consent for 




3.4.2 Airway obstruction 
Ventilatory function testing was performed using a portable, battery operated, ultrasound transit-time 
based spirometer (Easy-One; Model 2001 Diagnostic Spirometer, NDD Medical Technologies, 
Zurich, Switzerland). Calibration was checked daily with a 3-L syringe. Forced expiratory maneuvers 
were performed with the respondent seated according to American Thoracic Society (ATS) 
recommended guidelines and standardization of procedures: at least three acceptable maneuvers, 
with FVC and FEV1 reproducible within 200 ml. Satisfactory spirometric tests were performed in 
83.1% of the respondents. The respondent was given 1 puff (100 µg/puff) of inhaled ventolin 
immediately after pre-bronchodilator maneuvers, followed by 2 puffs of inhaled ventolin 5 min later. 
Chronic airflow obstruction was defined as Post-bronchodilator FEV1/FVC < 0.70, consistent with 
the clinical criteria of diagnosing airflow obstruction. 186 
 
3.4.3 Stressful life events and depressive symptoms 
Stressful life events were measured by the 11-item life events inventory 71, 187 that excluded personal 
illness experience directly related to airflow obstruction. The participants were asked to indicate yes 
or no as to whether any of eleven stressful life events had occurred over the past year (“spouse or 
partner die, a close friend or family member (other than spouse or partner) die or have a serious 
illness, major problems with money, a divorce or breakup, family member or close friend have a 
divorce or breakup, major conflict with children or grandchildren, major accidents, disasters, 
muggings, unwanted sexual experiences, robberies, or similar events, a family member or close 
friend lose job or retire, physically abused, verbally abused, or pet die”). If the participant indicated 
(a) life event(s) had occurred, he/she was asked to appraise the event and indicate on a scale of 1 (did 
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not upset me) to 3 (upset me greatly) the extent it upset them. The frequency of stressful life events 
was calculated for each respondent. The scale also provides a stressful life event score appraised by 
the participant that ranged from 0 to 33 with a higher score indicating a participant experienced a 
greater number of more stressful life events. 
 
The presence of depressive symptoms was determined by a depression screening scale for elderly 
populations, the 15-item Geriatric Depression Scale (GDS-15) with scores ranging from 0 to 15. 188 
The GDS was well suited for the study because it is largely free of the measurement artefact due to 
overlapping somatic symptoms of physical illness(es) and depression. Depressive symptoms defined 
by GDS ≥ 5 is clinically significant, and such cases including “sub-threshold” depression, had been 
shown in the same population to be associated with significantly poorer mental and physical health 
and functional status, and more healthcare resource utilization compared to non-cases and were 
similar to or worse than syndrome threshold cases of depression. 189 
 
3.4.4 Cognitive function 
Cognitive function was measured using the Cognitive Failures Questionnaire (CFQ) 190 and the Mini-
Mental State Examination (MMSE) 191 which were validated and widely used to assess global 
cognitive functioning. The CFQ uses a 5-point Likert-type scale (1 = Never, 5 = Very often) to 
evaluate self-reported cognitive problems (e.g.,‘‘Do you need to re-read instructions several times?”). 
Higher CFQ scores indicate more frequent cognitive problems. Higher MMSE scores (0 to 30) 
indicate better global cognitive functioning, and MMSE scores of 23 or less are considered to be 




3.4.5 Physical and mental functioning 
Physical and mental functional well-being was measured by the Medical Outcomes Study 36-item 
Short Form (SF-36) 192 which has been previously validated for use in Singaporeans 193. Weighted 
summary measures of PCS and MCS scores were computed with higher scores indicating better 
physical and mental health functioning and QoL. 
 
3.4.6 Statistical analyses 
In preliminary univariate analysis, participants with and without airway obstruction were compared 
with respect to differences in number of stressful life events, perceived stress score, level of FEV1, 
CFQ, MMSE, GDS depression, and SF-36 PCS and MCS scores, as well as potential confounding 
variables, sex, age, ethnicity, smoking status, number of chronic diseases, using t-tests or chi-squared 
tests of significance. The independent main effects of stressful life events and airway obstruction 
(independent variables) as well as the interaction of stressful life events and airway obstruction on 
measures of pulmonary function, depressive symptoms, cognitive function, and QoL (dependent 
variables) were analyzed using two-way ANOVA using generalized linear model which adjusted for 
sex, age, ethnicity, smoking status, and number of chronic illness. The independent variable of 
primary interest was stressful life events, and the primary outcome variables of interest were 
depressive symptoms and QoL. A secondary relationship analyzed in the two-way ANOVA model 
was the main effect of airway obstruction status (and its interaction with stressful life events) on 
primary outcomes of pulmonary and cognitive functions. For the outcome variables with significant 
interaction of stressful life events and airway obstruction, the simple effects of their relationships 
40 
 
with stressful life event score were investigated respectively in participants with and without airway 
obstruction.  
 
3.5 Study V: Stress, neuropeptide Y, and young adult asthma: a follow-up study 
3.5.1 Study design and participants 
In this clinical study, 70 young adults (aged 21-35 years) with physician-diagnosed asthma were 
recruited. They included 19 chronic asthma patients with acute exacerbations from EMD, 51 patients 
with stable chronic asthma on follow up in the clinics of the Division of Respiratory and Critical 
Care Medicine (RCCM) of NUH. A group of 69 healthy controls were age-matched (+/- 2 years) and 
gender-matched with asthma patients, without current or previous history of asthma and agreed to 
provide blood samples, health information and written informed consent. 
 
The inclusion criteria were: asthma patients a) with doctor-diagnosed asthma; b) present at EMD for 
acute exacerbations of asthma or on routine follow up at RCCM specialist clinics with known asthma 
in quiescent state (free of asthma attacks) for at least 3 months; c) aged 21-35 years; d) able to 
understand and respond to questions in English; healthy controls a) aged 21-35 years; b) able to 
understand and respond to questions in English. The exclusion criteria were individuals a) with other 
pulmonary disease (cystic fibrosis, etc.); b) having neurological or psychiatric illness (depression, 
schizophrenia, bipolar disorder, PTSD, ADHD, autistic disorder, etc.); c) having gastro-intestinal (e.g. 
irritable bowel syndromes), autoimmune disorders (arthritis, lupus, etc.), pituitary syndromes, 
Cushings syndrome, involving disturbances in the HPA axis; d) on oral steroid treatment within two 
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weeks before visiting; e) having mental incapacitation or learning disability with difficulty 
understanding and responding to questions in English. 
 
Interested volunteer patients and healthy controls were invited to attend a screening interview to 
assess their eligibility and provide informed consent before enrolment. After this, trained nurses 
would bring the participant to a designated room within the department that is free from distraction 
and where the conversation between the investigator and the participant could not be overheard. The 
participants’ demographics, asthma clinical, psychological, neuroendocrine and immunological 
profiles were assessed. Spirometric tests were administered and 20ml venous blood samples were 
collected into the BD Vacutainer® CPT™ Cell Preparation tube with sodium citrate. Samples were 
centrifuged at room temperature in a horizontal rotor for 20 minutes at 1650 rpm with the brake off. 
Within 2 hours after sample collection, plasma was isolated from each blood sample and stored in a 
−80°C freezer until the time the experiments were performed. At 12-month follow up, 63 asthma 
patients were successfully re-contacted. All participants signed written informed consent for the 
study, which was approved by the National Healthcare Group DSRB. 
 
3.5.2 Spirometric test 
Lung function testing was performed as described in 3.4.2. 
 
3.5.3 Questionnaire administration 
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Asthma control was measured using the ACT as described in 3.2.2. Asthma-related functional 
impairment was assessed using the Asthma Quality of Life Questionnaire (AQLQ) 194, 195 which is a 
validated questionnaire with excellent psychometric properties: the internal consistency reliability 
ranged from 0.90 to 0.95, and the reproducibility ranged from 0.81 to 0.93. 196 It consists of 32 items 
relating to day-to-day problems most troublesome to asthma patients. Consequences of asthma are 
evaluated in four life domains: activity limitations (ability to carry out daily activities), symptoms 
(frequency and nature of asthma symptoms such as coughing and chest tightness), emotional distress 
(intensity of the discomfort, fear, or distress associated with asthma), and exposure (to environmental 
stimuli) (capacity to manage environmental triggers of asthma such as smoke, dust, and pollution). 
Patients were asked to recall their experience over the previous 2 weeks and respond to each question 
on a 7-point scale. Average scores on each domain and a total AQLQ score were generated for each 
patient. 
 
The SRRS 155 was used to measure stress from major life events. The SRRS has been used widely in 
studies of psychosocial stress and illness. 197 Subjects were asked to rate which of a list of life events 
(e.g., ‘death of a spouse’, ‘divorce’, marital separation’, ‘jail term’, ‘death of a close family member’, 
‘personal injury or illness’, ‘marriage’, ‘fired at work’, etc.) had occurred over the past year. The 
score of "Life Change Units" was summed for each individual. Perceived stress was measured by 
Perceived Stress Scale which was detailed in 3.2.4.  
 
The Hospital Anxiety and Depression Scale (HADS) 198 was used to test anxiety and depression 
levels. The HADS is a 14-item scale consisting of 7 items related to anxiety and 7 items related to 
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depression. Participants rated on a 4-point response scale (from 0 representing absence of symptoms, 
to 3 representing maximum symptoms), and received a score ranging from 0 to 21 on each of the 
depression and anxiety subscales. The construction of the HADS avoids the use of somatic symptoms 
that may confound self-reported measures of depression and anxiety. 199, 200 
 
Neuroticism was measured by the Neuroticism subscale of the NEO Five-Factor Inventory (NEO-
FFI) which is designed to assess personality traits identified in the universal Five-Factor Model 
(FFM, openness, conscientiousness, extraversion, agreeableness and neuroticism). 201 Participants 
respond to a series of statements on a 5-point scale ranging from 1 (strongly disagree) to 5 (strongly 
agree), and a summed score of the 12 items is derived. The neuroticism subscale has high reliability 
and validity with a Cronbach’s α of 0.85. The psychometric properties and cross-cultural 
applicability of the NEO 201 has been substantiated in a validation study in Singapore. 202 
 
3.5.4 Enzyme-linked immunosorbent assay (ELISA) and Multiplex analysis 
Blood samples were collected during a 4-hour midday period (10:00-14:00 h) which is recommended 
to test cortisol levels because of the minimal fluctuation during this time. 79 Plasma specimens were 
prepared for ELISA and Multiplex analysis in 96-well plates. Neuropeptide Y-like immunoreactivity 
was measured using a competitive enzyme immunoassay (Bachem/Peninsula Laboratories Inc., San 
Carlos, California). Levels of ACTH and cortisol were determined using the ELISA kits from Alpco 
Diagnostics (Salem, New Hampshire). Noradrenaline and adrenaline concentrations were determined 
using commercially available ELISA kits from Abnova (Taipei City, Taiwan). Plates were run 




Plasma concentration of IL-4 was analysed utilizing a custom Milliplex MAP Human Cytokine 
Magnetic Bead Panel (Millipore Corp., Billerica, Massachusetts) following the kit-specific protocols 
provided by Millipore. Results were acquired using the Luminex 200 platform (Millipore), with 
Bioplex Manager 6.0 software, based on standard curves plotted through a 5-parameter logistic curve 
setting. 
 
3.5.5 Socio-demographic data and clinical profile 
Socio-demographic variables included gender, age, family housing type as a proxy for 
socioeconomic status (1-3 room public housing, 4-5 room public housing or private house), smoking 
status (non-smoker, past or current smoker), and BMI based on physical measurements of weight and 
height. Asthma-related clinical assessments consisted of frequency of asthma attack within the past 
one year, frequency of hospitalization due to asthma within the past one year, duration of history of 
asthma, and dose of ICS. SRH was assessed as described in 3.2.5. 
 
3.5.6 Statistical analyses 
The HPA stress response index was created as a composite index of cortisol, noradrenaline, 
adrenaline and ACTH using principal component analysis score. Three components were extracted 
with a percentage of cumulative covariance of 84.467% (λ = 0.9). The standardized regression factor 
scores for the three components were summed as HPA stress index based on respective variances 
explained. Differences in baseline socio-demographic status, asthma-related clinical variables, 
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asthma control and QoL, psychological variables, HPA index, and the levels of Th2 cytokine IL-4 
were compared among groups of participants with acute asthma, chronic asthma, and the healthy 
controls using 2-tailed Chi-squared test, t-test and One-way ANOVA. Partial correlations 
(controlling for age) between IL-4 level and psychological and biological stress variables were 
assessed in the whole sample, asthma and control groups. Dosage of inhaled corticosteroids was 
further controlled in the correlation between IL-4 and cortisol levels in the whole sample, and acute 
and chronic asthma groups considering that the cortisol levels in asthma patients may still be affected 
by past steroid treatment (54/70 patients at baseline in this study). 203 In generalized linear models, 
the associations of perceived stress, NPY, and HPA index with plasma IL-4 concentration were 
investigated among participants, controlling for potential confounders (gender, age, ethnicity, 
smoking status, family housing type, BMI, asthma severity, asthma control, and neuroticism). We 
evaluated the mediational role of NPY in two sets of regression models predicting plasma levels of 
IL-4 that related to (1) perceived stress as a predictor variable (psychological stress model) and (2) 
HPA Index as a predictor variable (biological stress model). We determined the association of 
perceived stress/HPA Index with IL-4, in the presence and absence of NPY, and evaluated the 
change in the strength and direction of association, the level of statistical significance and R-squared 





CHAPTER 4 RESULTS 
4.1 Study I: Prevalence of anxiety and depressive symptoms in adolescents with asthma: a 
meta-analysis and meta-regression 
Seven hundred and sixty-six abstracts were initially identified through database searches. We 
excluded 741 articles because they did not meet the inclusion criteria. In the remaining 25 articles, 9 
studies failed to include a healthy control group with a sample size of at least 50; 4 studies lacked 
standardized assessment of depressive and/or anxiety symptoms; 2 studies had the same data with 
other studies which were already included; 2 studies did not provide sufficient information to 
calculate an effect size. The selection process of papers was summarized in Figure 1. Finally, 8 
eligible articles 58, 204-210 were included in this meta-analysis. These studies were mainly conducted in 
Western countries and involved 3,546 patients and 24,884 healthy controls (Table 1). 
 
4.1.1 Aggregate prevalence and pooled odds ratio of depressive symptoms in adolescents with 
asthma versus the healthy controls 
The aggregate prevalence of depressive symptoms among adolescents with and without asthma using 
the random effects model was 0.27 (95% CI: 0.18-0.39) and 0.13 (95% CI: 0.09-0.19) respectively 
(Figure 2A-B). The risk of developing depressive symptoms was significantly higher in patients with 
asthma than that in the healthy controls (OR = 2.09, 95% CI: 1.65-2.64, Z = 6.154, p < 0.001). 
Figure 3A shows the forest plot generated for the pooled odd ratio of depressive symptoms in the 
asthma and the control groups from the studies. Statistically significant heterogeneity (tau² = 0.068, 
Q = 30.0, df = 7, p < 0.001, I2 = 76.7) was present when calculating the OR. Mixed-model meta-


























766 citations identified using search strategy. 
741 citations irrelevant or failure to meet inclusion 
criteria excluded: 
•Irrelevant to asthma: 282 studies. 
• Not focused on anxiety/depressive symptoms-
asthma association: 276 studies.  
•Review: 22 studies. 
•Case report: 2 studies.  
•Age range beyond 12-18 years: 117 studies. 
•On psychological intervention: 27 studies. 
•On subtypes of asthma or comparison of asthma 
with other diseases: 15 studies. 
25 articles selected for assessment against the 
inclusion and exclusion criteria or screening for 
additional potentially relevant citations. 
17 articles excluded: 
•Without a proper control group: 9 studies. 
• Without standardized assessment of depressive 
or anxiety symptoms: 4 studies.  
•Insufficient information to calculate a 
standardized effect size: 2 studies. 
•Data duplicating selected studies: 2 studies. 











Table 1. Study design and baseline characteristics of studies included in meta-analysis 
 
 Study name and 
location 
Study design Description of 
asthma patients 




female in all 
subjects (%) 



















Smokers in all 
subjects (%) 
Proportion of 
severe asthma in 
asthma patients 
(%) 
              
Otten 204 Across Netherlands Observational 
cohort study 
Population-based 




600/4553 52.2 12.97 NA Depressive Mood List/NA 21.3/10.7 NA 38.5 17.6 
 
             
Bender 205 YRBS of US Observational 
cohort study 
Self-report of asthma 
diagnosis 
All others considered no-
asthma 
718/13148 51.9 NA 44.0 5 questions from 
YRBS/NA 
45.3/29.3 NA 20.6 NA 
              





of asthma diagnosis 
and medication 
No asthma diagnoses or 
medication use 
781/598 48.3 14.04 6.9 Mood and Feelings 
Questionnaire/ASI 
7.3/4.0 18.7/9.1 4.5 30.3 
              




Self-report of asthma 
diagnosis 
Those without experience 
of asthma 
386/1650 49.8 NA NA CIDI/CIDI 32.4/20.6 21.0/13.6 NA NA 
              




25 adolescents with 
asthma 
25 matched controls 25/25 52.0 18.5 36.0 Back Depression 
Inventory/Back Anxiety 
Inventory 
32.0/8.0 32.0/24.0 NA NA 
              
Ortega 208 MECAMDS in 
Atlanta, New Haven, 




Parental reports of 
asthma 
Youths from selected 
communities 
199/1059 47.0 NA 51.7 DISC/DISC 13.4/11.7 49.2/37.7 NA NA 
              









797/3751 51.0 13.52 82.0 HBSC survey instrument/ 
HBSC survey instrument 
42.4/30.4 50.1/35.0 NA NA 
              
Seigel 210 New York Case-
controlled 
Outpatients Matched for 
socioeconomic status 
40/100 NA NA NA BDI/NA 62.5/13.0 NA NA 100.0 
              
YRBS = Youth Risk Behaviour Survey; CHDS = Christchurch Health and Development Study; MECAMDS = Methods for the Epidemiology of Child and Adolescent Mental Disorders study; ISAAC = Standardized 
methodology of the International Study of Asthma and Allergy in Childhood; YRBS= Youth Risk Behaviour Survey; ASI = Childhood Anxiety Sensitivity Index; CIDI = Composite International Diagnostic Interview; 
DISC = Diagnostic Interview Schedule for Children; HBSC = Health Behaviour Among School Children; BDI = Beck Depression Inventory. 
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and disease-related factors including age, gender, ethnicity, smoking status and severity of asthma) in 
all studies. Results showed that the mean age (B= -1.444, z = -0.826, p = 0.409) and the proportion of 
female (B = -3.850, z = -1.815, p = 0.069) of all subjects and the severity of asthma (B = -0.030, z = -
0.053, p = 0.958) of asthma patients were non-significant moderators. However, proportions of 
Caucasian (B = 0.746, z = 2.665, p = 0.008) and smokers (B = 0.875, z = 4.383, p < 0.001) in the 
sample were significant moderators for heterogeneity (Table 2). 
 
We also tested for the presence of publication biases using funnel plots and Egger's regression test. 211 
No significant publication bias was detected (intercept = 1.29, SE = 1.38, 95% CI: -2.08-4.66, t = 
0.94, df = 6, p = 0.384) of all studies. 
 
4.1.2 Aggregate prevalence and pooled odds ratio of anxiety symptoms in adolescents with 
asthma versus the healthy controls 
The aggregate prevalence of anxiety symptoms among the asthma patients and the healthy controls 
was 0.33 (95% CI: 0.19-0.52) and 0.21 (95% CI: 0.12-0.33), respectively (Figure 2C-D). Three 
studies were not used in synthesizing the effect size of the aggregate prevalence of anxiety symptoms 
as they did not report data on anxiety symptoms. 204, 205, 210 (Table 1) The risk of developing anxiety 
symptoms was significantly higher in asthma patients compared with the healthy controls (OR = 1.83, 
95% CI: 1.63-2.07, Z = 9.876, p < 0.001; Figure 3B). No significant heterogeneity (tau² = 0.000, Q = 
3.3, df = 7, p = 0.517, I2 = 0.0) and no publication bias (intercept = -11.25, SE = 10.26, 95% CI: -




















C. Forest plot of the aggregate prevalence of anxiety symptoms in adolescents with asthma            D. Forest plot of the aggregate prevalence of anxiety symptoms in healthy adolescents 





A. Forest plot of the pooled odd ratio of depressive symptoms in adolescents with and without asthma                  B. Forest plot of the pooled odd ratio of anxiety symptoms in adolescents with and without asthma 




Table 2. Meta-regression analysis of potential moderators to explain 
heterogeneity of prevalence of depressive symptoms 
 
Factor Regression 
Coefficient (SE)    
Z Score Tau
2
 df p 
      
Mean Age, years -1.444 (1.748) -0.826 0.000 2 0.409 
Female, % -3.850 (2.121) -0.053 0.005 5 0.958 
Caucasian, % 0.746 (0.280) 2.665 0.026 3 0.008 
Severe asthma, % -0.030 (0.563) -0.053 0.124 1 0.958 
Smokers, % 0.875 (0.200) 4.383 0.000 1 <0.001 
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4.2 Study II: Asthma control, perceived stress, and quality of life in adolescents with asthma: a 
case-control study 
4.2.1 Demographics 
There were significant differences in ethnicity (p < 0.01) and housing types (p < 0.01) among the 
three groups. Asthma patients had significantly higher proportions of Malays and Indians and were 
more likely to reside in smaller public housing as compared to the healthy controls. No significant 
difference was observed in age and gender among the three groups (p > 0.05). Higher proportions of 
smokers (p < 0.05), higher BMI (p < 0.01) and poorer self-rated health status (p < 0.01) were 
observed among asthma patients, especially those with poorly controlled asthma, when compared to 
the healthy controls. 
 
4.2.2 Asthma control 
Among asthma patients, the mean asthma control score was 22.6 (SD: 1.80) for those with well 
controlled asthma and 16.2 (SD: 2.78) for those with poorly controlled asthma (p < 0.001). 
Participants with poorly controlled asthma had significantly lower scores (p < 0.001) on asthma 
quality of life (overall and on activity limitation, asthma symptom and emotional function) than those 
with well controlled asthma. (Table 3) 
 
4.2.3 Psychiatric comorbidities 
Adolescents with poorly controlled asthma reported significantly more severe panic attacks, 
depressive symptoms and total internalizing symptoms than respondents with well controlled asthma 
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and the healthy controls (p < 0.05). Respondents with poorly-controlled asthma had significantly 
more severe generalized anxiety symptoms in comparison to the healthy controls (p < 0.05), and 
more severe obsession and compulsion and total anxiety symptoms than well controlled asthma 
patients (p < 0.05). There was no significant difference in the symptom scores of social phobia and 
separation anxiety among the three groups (p > 0.05). (Table 3) 
 
By classifying the number of participants with symptom scores above the borderline and reaching the 
clinical thresholds of psychiatric comorbidities, the number of subjects who were disturbed by severe 
panic attacks and depressive symptoms was found to be higher among participants with asthma, 
especially those with poorly controlled asthma, than their healthy counterparts (p < 0.05). No 
significant difference was observed in social phobia, separation anxiety, generalized anxiety, 
obsession and compulsion, total anxiety, and total internalizing symptoms among the respondents. 
(Table 3) 
 
To control for confounding variables, we adjusted the mean psychiatric comorbidity score for the 
difference in gender, age, ethnicity, smoking status and family housing type among the well 
controlled and poorly controlled asthma and the healthy control groups in analysis of covariance 
(ANCOVA) models. As shown in Table 4 (base model), the same difference in scores for panic 
attacks, depression and total anxiety and internalizing symptoms among the three groups remained 
statistically significant after adjustment. 
 
4.2.4 Contribution of perceived stress to psychiatric comorbidity 
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Although no significant difference was observed in the number of stressful life events among the 
respondents, participants with poorly controlled asthma scored significantly higher on perceived 
stress than the other two groups (p < 0.05). Correlational analyses for the whole sample revealed that 
perceived stress score was significantly correlated with scores of all psychiatric comorbidities (p < 
0.001). (Table 5) Among asthma patients, asthma control score was negatively correlated with 
perceived stress and symptom scores of all psychiatric comorbidities (p < 0.05), except for social 
phobia (p > 0.05). 
 
Multivariate analyses were performed to determine how much of the difference in symptom scores of 
panic attacks, depression, total anxiety and total internalizing scales among the well-controlled, 
poorly controlled asthma and the healthy control groups were explained by the levels of perceived 
stress. Table 4 shows the adjusted mean scores for panic attacks, depression, total anxiety and total 
internalizing symptoms in generalized linear models when perceived stress was added into the model. 
Perceived stress made a large contribution (R2 changed from 18% to 29%) to the variations in the 
severity of psychiatric comorbidities, and its inclusion in the model resulted in substantial decrease in 
the differences for total anxiety and total internalizing symptoms. No significant differences were 
found in the scores of total anxiety and total internalizing symptoms between asthma patients and the 
healthy controls after accounting for the difference in perceived stress. 
 
Among asthma patients, higher asthma control score was associated with lower scores in total 
anxiety, depression and internalizing symptoms (p < 0.01). (Figure 4) To evaluate the mediating 
effect of perceived stress on the relationship between asthma control and severity of psychiatric 
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comorbidities, we evaluated this relationship after inclusion of perceived stress in the hierarchical 
model, with covariate adjustment for gender, age, ethnicity, smoking status and family housing type. 
(Table 6) In the presence of perceived stress, asthma control was not significantly associated with 
psychiatric comorbidities any more except for panic attacks (p = 0.036), and perceived stress 
remained strongly associated with depression, panic attacks, total anxiety and total internalizing 
symptoms (p < 0.001).  
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Table 3. Socio-demographic characteristics, psychological functioning, clinical profiles and psychiatric 
comorbidity of adolescents with and without asthma (n = 369) 
 Poorly controlled  










      
Gender       
   Male 36 (59.0) 82 (59.9) 87 (50.9) χ2 = 2.837 0.242 
   Female 25 (41.0) 55 (40.1) 84 (49.1)   
Age (yrs) 15.10 ± 2.75 15.06 ± 2.63 14.90 ± 2.43 F = 0.208 0.813 
Ethnicity      
  Chinese 26 (42.6) 66 (48.2) 113 (66.1) χ2 = 17.668 0.001 
  Malay 19 (31.1) 40 (29.2) 24 (14.0)   
  Indian or others 16 (26.2) 31 (22.6) 34 (19.9)   
Smoking status      
  Non smoker 52 (85.2) 125 (91.2) 165 (96.5) χ2 = 9.052 0.011 
  Past or current smoker 9 (14.8) 12 (8.8) 6 (3.5)   
Family housing type      
  1-2 room public housing 5 (8.2) 2 (1.5) 2 (1.2) χ2 = 21.168 0.002 
  3 room public housing 7 (11.5) 17 (12.6) 30 (17.5)   
  4-5 room public housing 45 (73.8) 101 (74.8) 135 (78.9)   
  Private housing or detached house 4 (6.6) 15 (11.1) 4 (2.3)   
BMI 21.51 ± 5.55* 21.48 ± 5.79* 19.75 ± 3.95 F = 5.255 0.006 
Self-rated health 2.96 ± 0.66***+++ 3.40 ± 0.61** 3.68 ± 0.68 F = 28.047 <0.001 
Neuroticism 22.05 ± 7.68*+ 18.91 ± 7.50 19.23 ± 7.61 F = 3.722 0.025 
No. of stressful life events 2.80 ± 2.49 3.02 ± 2.86 2.57 ± 2.31 F = 1.127 0.325 
Perceived stress score 18.25±5.11+ 16.15±5.72 17.51±5.39 F = 3.848 0.022 
      
Asthma control score 16.22 ± 2.78 22.64 ± 1.80 NA t = 15.705 <0.001 
Pediatric asthma quality of life 4.51 ± 1.30 6.06 ± 0.85 NA t = 9.656 <0.001 
Activity limitation 4.59 ± 1.42 6.38 ± 0.91 NA t = 10.348 <0.001 
Symptom 4.61 ± 1.40 6.03 ± 0.91 NA t = 8.224 <0.001 
Emotional function 4.34 ± 1.26 5.91 ± 1.01 NA t = 8.972 <0.001 
      
 Social phobia 46.00 ± 12.01 44.65 ± 10.28 44.54 ± 9.95 F = 0.462 0.630 
    No 56 (93.3) 130 (96.3) 163 (95.9) χ2 = 2.109 0.701 
    Borderline 2 (3.3) 4 (3.0) 5 (2.9)   
    Yes 2 (3.3) 1 (0.7) 2 (1.2)   
 Panic attacks 55.08 ± 18.65***++ 48.02 ± 12.44 47.61 ± 10.86 F = 7.942 <0.001 
    No 50 (83.3) 124 (91.2) 155 (90.6) χ2 = 11.127 0.025 
    Borderline 0 (0.0) 3 (2.2) 7 (4.1)   
    Yes 10 (16.7) 9 (6.6) 9 (5.3)   
 Depression 51.32 ± 15.63**++ 45.23 ± 11.85 44.93 ±10.87 F = 6.694 0.001 
    No 49 (81.7) 127 (94.1) 156 (91.8) χ2 = 9.600 0.048 
    Borderline 5 (8.3) 3 (2.2) 9 (5.3)   
    Yes 6 (10.0) 5 (3.7) 5 (2.9)   
 Separation anxiety 54.54 ± 14.17 50.39 ± 10.47 51.42 ±12.43 F = 2.460 0.087 
    No 47 (79.7) 125 (91.9) 144 (84.2) χ2 = 6.887 0.142 
    Borderline 4 (6.8) 5 (3.7) 11 (6.4)   
    Yes 8 (13.6) 6 (4.4) 16 (9.4)   
 Generalized anxiety 47.75 ± 13.85* 44.79 ±12.68 42.95 ± 10.12 F = 3.806 0.023 
    No 52 (86.7) 126 (92.6) 165 (96.5) χ2 = 8.816 0.066 
    Borderline 3 (5.0) 6 (4.4) 2 (1.2)   
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    Yes 5 (8.3) 4 (2.9) 4 (2.3)   
 Obsession and compulsion 50.85 ± 11.99+ 46.38 ± 11.26 46.19 ± 9.68 F = 4.613 0.011 
    No 53 (88.3) 128 (94.8) 159 (93.0) χ2 = 5.138 0.273 
    Borderline 3 (5.0) 2 (1.5) 8 (4.7)   
    Yes 4 (6.7) 5 (3.7) 4 (2.3)   
 Total anxiety symptoms 47.44 ±18.15+ 40.07 ± 17.32 42.56 ± 16.37 F = 3.851 0.022 
    No 51 (86.4) 124 (92.5) 154 (91.1) χ2 = 4.575 0.334 
    Borderline 2 (3.4) 6 (4.5) 7 (4.1)   
    Yes 6 (10.2) 4 (3.0) 8 (4.7)   
 Total internalizing symptoms 48.46 ± 18.13*++ 40.68 ± 15.21 42.47 ± 14.68 F = 5.234 0.006 
    No 50 (84.7) 125 (93.3) 153 (90.5) χ2 = 6.226 0.183 
    Borderline 2 (3.4) 4 (3.0) 8 (4.7)   
    Yes 7 (11.9) 5 (3.7) 8 (4.7)   
      
 
Data are presented as n (%) or M±SD. ** p < 0.01, * p < 0.05 vs. the healthy control group. +++ p < 0.001, ++ p < 
0.05, + p < 0.05 vs. the well controlled asthma group. The score of total anxiety symptoms is the sum of the 5 
anxiety subscales including panic attacks, social phobia, generalized anxiety, obsession and compulsion, and 
separation anxiety. Total internalizing symptoms score is the sum of all 6 subscales. 
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Table 4. Adjusted mean ± standard error symptom scores of psychiatric comorbidity among poorly controlled 
and well controlled asthma patients, and healthy adolescents: hierarchical regression models 
 
 Poorly controlled  
(n = 61) 
Well 
controlled  
(n = 137) 
Healthy control  
(n = 171) F p R
2
 change 
       
Base Model: Gender, age, ethnicity, smoking status and family housing type.  
Depression 52.57 ± 1.81**++ 47.18 ± 1.53 46.87 ± 1.56 5.152 0.006  
Panic attacks 56.49 ± 1.96***+++ 49.77 ± 1.64 50.03 ± 1.68 6.229 0.002  
Social phobia 47.81 ± 1.56 47.21 ± 1.32 47.59 ± 1.34 0.084 0.92  
Separation anxiety 56.92 ± 1.82 53.55 ± 1.52 55.11 ± 1.55 1.649 0.194  
Generalized anxiety 50.05 ± 1.76 47.87 ± 1.48 4.71 ± 1.51 1.722 0.180  
Obsession and compulsions 53.32 ± 1.57 50.02 ± 1.32 50.33 ± 1.35 2.221 0.110  
Total anxiety symptoms 50.76 ± 2.56+ 44.33 ± 2.15 48.05 ± 2.19 3.294 0.038  
Total internalizing symptoms 52. 99 ± 2.37++ 46.20 ± 2.02 49.01 ± 1.98 4.110 0.017  
       
Base model plus perceived 
stress 
      
Depression 52.56 ± 1.64* 49.22 ± 1.41 47.86 ± 1.38 4.270 0.015 0.256 
Panic attacks 56.73 ± 1.86** 52.28 ± 1.60 51.22 ± 1.57 4.632 0.010 0.183 
Total anxiety symptoms 48.07 ± 2.26 44.75 ± 1.94 46.48 ± 1.90 1.163 0.314 0.258 
Total internalizing symptoms 50.18 ± 2.02 46.34 ± 1.74 47.45 ± 1.70 1.774 0.171 0.287 
       
 
Figures shown are Bonferroni-adjusted mean ± standard errors estimated from ANCOVA models. 
*** p < 0.001, ** p < 0.01, * p < 0.05 vs. the healthy control group. +++ p < 0.001, ++ p < 0.05, + p < 0.05 vs. the 





























Perceived stress Score 1 -0.166 0.501*** 0.375*** 0.460*** 0.395*** 0.442*** 0.401*** 0.528*** 0.534*** 
Asthma control Score  1 -0.087 -0.224 -0.247*** -0.202** -0.143 -0.165 -0.200 -0.240** 
Social phobia   1 0.539*** 0.624*** 0.538*** 0.694*** 0.630*** 0.822*** 0.815*** 
Panic attacks    1 0.710*** 0.504*** 0.645*** 0.675*** 0.650*** 0.703*** 
Depression     1 0.536*** 0.660*** 0.643*** 0.647*** 0.774*** 
Separation anxiety      1 0.566*** 0.584*** 0.669*** 0.693*** 
Generalized anxiety       1 0.725*** 0.789*** 0.802*** 
Obsession and compulsion        1 0.741*** 0.756*** 
Total anxiety symptoms         1 0.954*** 
Total internalizing symptoms          1 
 
   *** p < 0.0009 by Holm-Bonferroni correction.  ** p<0.01 
     + 









Figure 4. Association of asthma control with psychiatric comorbidity in adolescents with asthma  




Table 6. Analyses of perceived stress and asthma control score as predictors of psychiatric 
comorbidity among asthma patients in regression models (n = 198) 
 
  Individual model entry*  Simultaneous model entry* 
  
B  SE β p 
Multiple 
R2 
 B  SE β p 
Multiple 
R2 
           
Dependent variable: Depression         
 Independent variables:          
 Perceived stress score 1.11  0.15 0.47 <0.001 0.269  1.06  0.16 0.45 <0.001 0.282 
 Asthma control score -0.84  0.25 -0.23 0.001 0.114  3.34  1.86 0.16 0.073 
           
Dependent variable: Panic attacks          
 Independent variables:          
 Perceived stress score 0.93  0.12 0.39 <0.001 0.208  0.95  0.18 0.36 <0.001 0.193 
 Asthma control score -0.87  0.29 -0.22 0.003 0.076  4.62  2.19 0.14 0.036 
           
Dependent variable: Total anxiety         
 Independent variables:          
 Perceived stress score 1.63  0.14 0.53 <0.001 0.312  1.67  0.20 0.52 <0.001 0.321 
 Asthma control score -0.84  0.35 -0.17 0.018 0.063  3.14  2.43 0.08 0.197 
           
Dependent variable: Total internalizing         
 Independent variables:          
 Perceived stress score 1.52  0.13 0.54 <0.001 0.342  1.54  0.19 0. 52 <0.001 0.345 
 Asthma control score -0.91  0.32 -0.21 0.005 0.097  3.70  2.21 0.10 0.095 
           
 
Data were adjusted for gender, age, ethnicity, smoking status and family housing type. 
* Individually: each independent variable (perceived stress score and asthma control score) was entered individually 
into the regression models; Simultaneously: all independent variables (perceived stress score and asthma control 
score) were entered simultaneously at the regression model. 
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4.3 Study III: Asthma, psychological stress and psychiatric comorbidity: a population-based 
study in adult Singaporeans 
4.3.1 Study participants 
Among the 2,847 respondents, 144 (5.1%) reported having asthma, of a mean duration of 12.2 (SD: 
11.1) years, and mean number of doctor visits of 2.3 (SD, 4.2, range: 0-30) in the last 12 months; 8 of 
them (5.6%) reported having been hospitalized for 1 to 3 episodes of asthma in the last 12 months.  
Consistent with our previous findings, 165, 212 participants with asthma tended to be younger, and were 
more likely to be Malay and less likely to be Chinese. A total of 843 (29.6%) participants reported 
having other chronic physical conditions (10.3% hypertension, 8.2% lipid abnormalities, 6.4% 
diabetes, 2.6% coronary and heart conditions, 4.1% arthritis, 1.5% cataract, 0.2% chronic obstructive 
pulmonary disease, 0.5% stroke, 0.3% hip fracture, 0.6% cancer, 0.2% kidney failure, 0.8% urinary 
disorders, and 12.8% others). A total of 1860 respondents reported no chronic physical illnesses 
(65.3%). The demographic profiles of the respondents are shown in Table 7 by groups of asthma (A), 
other chronic physical conditions (B), and no chronic physical condition (C). 
 
A total of 520 (18.3%) individuals had a score of GHQ ≥ 2 and were further administered SCAN. 
Case-level diagnosis of any psychiatric disorder was made for 7.3% of respondents (n = 208), MDD 
for 5.8% (n = 164), and GAD for 3.1% (n = 89). A total of 311 respondents reported 1 to 2 stressful 
life events (10.9%) and another 82 respondents reported having 3 or more stressful life events (2.9%) 
in the previous 6 months. 
 




             Table 7. Socio-demographic and clinical characteristics of adults aged 20-59 by asthma, other chronic physical conditions, and 




Other Chronic Physical 
Conditions  (B) 
No Chronic Physical 
Conditions (C) 
Significance Tests 
(A) vs (B) vs (C)  p 
      
No. of respondents (n = 106) (n = 843) (n = 1860)   
      
Female sex 80 (75.5) 513 (60.9)
 
 1174 (63.1) χ2 = 8.73, 2df 0.013 
Age      
   20-34 45 (42.5) 98 (11.6) 649 (34.9)   
   35-44 29 (27.4) 266 (31.6) 748 (40.2)   
   45-59 32 (30.2) 479 (56.8) 463 (24.9) χ2 = 305.06, 4df <0.001 
Ethnicity       
   Malay 47 (44.3) 243 (28.8) 656 (35.3)   
   Chinese  19 (17.9) 290 (34.4) 600 (32.3)   
   Indian 40 (37.7) 310 (36.8) 604 (32.5) χ2 = 22.41, 4df <0.001 
Employment      
   Employed  70 (66.0) 496 (58.8) 1173 (63.1)   
   Housewives, retired, students 36 (34.0) 347 (41.2) 687 (36.9) χ2 = 5.19, 2df 0.075 
Marital status       
   Married 76 (71.7) 655 (77.7) 1410 (75.8)   
   Unmarried 30 (28.3) 188 (22.3) 450 (24.2) χ2 = 2.39, 2df 0.303 
Formal Education      
   No education 5 (4.7) 46 (5.5) 52 (2.8)   
   Primary to secondary 77 (72.6) 626 (74.3) 1257 (67.6)   
   Post-secondary and tertiary 24 (22.6) 171 (20.3) 551 (29.6) χ2 = 35.06, 4df <0.001 
No. of coexisting chronic illness      
   0-2 106 (100.0) 746 (88.5) 1860 (100.0)   
   3 or more 0 (0.0) 97 (11.5) 0 (0.0) χ2 = 234.31, 2df <0.001 
      
                            
                     Figures in table denote number and %. 
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                        Table 8.  Prevalence (%) of psychiatric disorders and stressful life events, by asthma, other chronic physical conditions                               
and no chronic physical conditions groups 
 
Asthma (A) 
Other Chronic Physical 
Conditions  (B) 
No Chronic Physical 
Conditions (C) 
Significance Tests p 
      
Any psychiatric disorder  15 (14.2) 105 (12.5) 88 (4.7) χ2 = 57.79, 2df <0.001 
Major depression disorder  14 (13.2) 82 (9.7) 68 (3.7) χ2 = 49.78, 2df <0.001 
Generalized anxiety disorder  7 (6.6) 40 (4.7) 42 (2.3) χ2 = 15.93, 2df <0.001 
      
No of life events       
  1-2 17 (16.0) 134 (15.9) 160 (8.6)   
  3 or more 15 (14.2) 30 (3.6) 37 (2.0) χ2 = 91.48, 4df <0.001 
      
Type of life events      
  Threat 7 (6.6) 58 (6.9) 53 (2.8)   
  Loss 5 (4.7) 32 (3.8) 51 (2.7)   
  Mixed 19 (17.9) 74 (8.8) 93 (5.0) χ2 = 68.94, 4df <0.001 
      
                             





Table 9. Association of asthma and other chronic physical conditions with measures of coexisting psychiatric disorders and stressful life events 
 
 Controlling 
for life events 
Asthma vs Other Chronic 
Physical Conditions 
 
Asthma vs No Chronic 
Physical Conditions 
 
Other Chronic Physical Conditions 
vs No Chronic Physical Conditions 
 OR (95% CI) p  OR (95% CI) p  OR (95% CI) p 
             
Number of life events (vs. none)             
   1-2 NA 1.16 0.66-2.06 0.605  2.32 1.33-4.06 0.003  1.99 1.52-2.62 <0.001 
   3 or more NA 4.33 2.09-8.95 <0.001  7.64 3.87-15.06 <0.001  1.77 1.01-3.11 0.049 
             
Any psychiatric disorder  No 1.17 0.63-2.18 0.622  2.86 1.54-5.28 0.001  2.44 1.75-3.42 <0.001 
 Yes 0.66 0.32-1.38 0.269  1.27 0.61-2.63 0.528  1.91 1.32-2.76 0.001 
             
Major depressive disorder  No 1.46 0.76-2.79 0.255  3.54 1.86-6.72 <0.001  2.43 1.66-3.55 <0.001 
 Yes 0.95 0.46-1.98 0.886  1.77 0.85-3.70 0.129  1.87 1.25-2.79 0.002 
             
Generalized anxiety disorder No 1.58 0.66-3.79 0.303  2.51 1.06-5.92 0.036  1.58 0.95-2.63 0.076 
 Yes 1.09 0.43-2.76 0.861  1.30 0.51-3.33 0.588  1.19 0.71-2.01 0.504 
             
           
                * Odds ratios were adjusted for sex, age, ethnicity, employment status, marital status, education, number of coexisting chronic illnesses.  
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As shown in Table 8, there were significantly greater prevalence of any psychiatric disorder, MDD 
and GAD among respondents with asthma (A) and other chronic physical conditions (B), compared 
to respondents with no chronic physical conditions (C). The odds ratio of association with any 
psychiatric disorder, MDD and GAD for A versus C, and with any psychiatric disorder and MDD for 
B versus C remained significantly elevated (OR point estimates ranging from 2.4 to 3.5) after 
adjusting for group differences in sex, age, ethnicity, employment status, marital status, education, 
and number of coexisting chronic medical conditions. (Table 9) Only the OR of association with 
GAD for B versus C was not significant after adjusting for potential confounders (OR = 1.58, 95% 
CI: 0.95-2.63). (Table 9) 
 
4.3.3 Stressful life events as a mediating factor for psychiatric comorbidity 
Considerably greater numbers of stressful life events were reported among respondents with asthma 
(14.2% with 3 or more stressful life events), much more than those reported by respondents with 
other chronic physical conditions (3.6%) and without chronic physical conditions (2.0%).  
Participants with asthma were found to have a high proportion of mixed threat and loss type of life 
events. (Table 8) Notably, respondents with asthma were 4 times more likely to report 3 or more life 
events compared to respondents with other chronic physical conditions (adjusted OR = 4.33, 95% CI: 
2.09-8.95, p < 0.001) (Table 9).    
 
We determined in hierarchical models whether stressful life events explained to a greater extent the 
comorbidity of psychiatric disorders in asthma than it did for other chronic physical conditions 
(Table 9). The addition of the frequency of stressful life events into the models substantially reduced 
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the significance of the OR estimates for asthma versus no chronic physical conditions for 
comorbidity of MDD (OR decreased from OR = 3.54, 95% CI: 1.86-6.72, p < 0.001 to OR = 1.77, 
95% CI: 0.85-3.70, p = 0.129), GAD (OR decreased from OR = 2.51, 95% CI: 1.06-5.92, p = 0.036 
to OR = 1.30, 95% CI: 0.51-3.33, p = 0.588) and any psychiatric disorder (OR decreased from OR = 
2.86, 95% CI: 1.54-5.28, p < 0.001 to OR = 1.27, 95% CI: 0.61-2.63, p = 0.528). The OR estimates 
for other chronic physical conditions (B) versus no chronic physical conditions (C) were found to 
remain significantly elevated. Consistently, Sobel test (Table 10) revealed that the presence of 
stressful life events, particularly 3 or more stressful life events, mediated the relationship between 
asthma and co-occurring case diagnosis of any psychiatric disorder, MDD and GAD. On the other 
hand, the mediational effect of stressful life events was not found for the association between other 
chronic physical conditions and psychiatric disorders (p > 0.05). 
 
4.3.4 Relative contribution of stressful life events and concurrent psychiatric disorders to 
impaired quality of life 
Next, we compared QoL scores among the study groups, and examined the relative contributions of 
stressful life events, any psychiatric disorder, MDD and GAD in hierarchical models to the 
differences in this relationship (Table 11). In the base model controlling for potential confounders, 
QoL scores were significantly lower for respondents with asthma (A) and with other chronic physical 
conditions (B), compared with those without chronic physical conditions (C) (p < 0.001). The 
difference in QoL between asthma (A) and no chronic physical conditions (C) virtually disappeared 
after accounting for number of stressful life events, but not after accounting for other psychiatric 
variables. The difference in QoL between groups with other chronic physical conditions (B) and 
without chronic physical conditions (C) remained significant even after adjusting for number of 
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stressful life events and other psychiatric variables. 
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Table 10. Sobel test of the mediation of stressful life events on the coexistence of psychiatric disorders with 
asthma andwith other chronic physical conditions 
 
 
Asthma vs Other Chronic 
Physical Conditions 
 
Asthma vs No Chronic 
Physical Conditions 
 
Other Chronic Physical 
Conditions vs No Chronic 
Physical Conditions 
 z p  z p  z p 
            
Any psychiatric disorder          
   1-2 life events 0.030 0.976  2.507 0.012  1.701 0.089 
   3 or more life events  4.210 <0.001  6.317 <0.001  0.937 0.349 
         
Major depressive disorder          
   1-2 life events 0.030 0.976  2.508 0.012  1.567 0.117 
   3 or more life events  4.131 <0.001  6.010 <0.001  0.909 0.363 
         
Generalized anxiety disorder         
   1-2 life events 0.026 0.979  2.466 0.014  1.435 0.151 
   3 or more life events  2.291 0.022  5.361 <0.001  0.732 0.464 
            
 





Table 11. Quality of life among asthma, other chronic physical conditions and no chronic physical conditions  
groups, and relative contributions from stressful life events and coexisting psychiatric disorders 












F (2,2844),    p 
 
Estimated Mean  
Difference ± SE 
A minus B A minus C 
         
Base Model NA 50.34 ± 0.75
***
 51.60 ± 0.43
***
 52.81 ± 0.44 12.93 <0.001 -1.25 ± 0.70 -2.47 ± 0.68 
         
Plus No. of life events 0.162 47.39 ± 0.70 47.30 ± 0.44
*
 47.98 ± 0.45 3.12 0.044 0.08 ± 0.65 -0.59 ± 0.62 
Plus Any psychiatric disorder  0.105 47.85 ± 0.72
*
 48.95 ± 0.43
*
 49.65 ± 0.45 6.10 0.002 -1.10 ± 0.66 -1.80 ± 0.64 
Plus Major depressive disorder  0.077 47.80 ± 0.74
*
 48.76 ± 0.45
*
 49.59 ± 0.47 6.83 0.001 -0.95 ± 0.67 -1.78 ± 0.65 
Plus Generalized anxiety disorder 0.029 47.60 ± 0.79
**
 48.72 ± 0.52
***
 49.84 ± 0.54 11.24 <0.001 -1.11 ± 0.69 -2.24 ± 0.67 
         
                 
        Base model: adjusted for sex, age, ethnicity, employment status, marital status, education, number of coexisting chronic illness.  
        
***
 p < 0.001, 
**
 p < 0.01, 
*
 p < 0.05 versus no chronic physical conditions group. 
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4.4 Study IV: The impact of stressful life events on quality of life in the elderly with airway 
obstruction 
This study consisted of 497 participants with the average age of 72.1. Among the respondents, 32.9% 
had airway obstruction, and 67.1% had no airway obstruction. The proportion of respondents with 
stressful life events in the past one year was 43.4%. The socio-demographic and psychological 
characteristics of study participants with and without airway obstruction are shown in Table 12. 
Participants with airway obstruction had higher mean age (t = 3.328, p = 0.001), higher proportion of 
smokers (χ2 = 20.586, df = 3, p < 0.001) and increased number of diseases (t = 7.096, p < 0.001). No 
significant difference in the number of stressful life events or perceived stress was observed between 
airway obstructive and non- airway obstructive participants (p > 0.05).   
 
Table 12 shows that compared with those without airway obstruction, respondents with airway 
obstruction had decreased post-bronchodilator FEV1 (t = 6.185, p < 0.001), MMSE score (t = 3.090, 
p = 0.002) and SF-36 PCS (t = 2.726, p = 0.007) score. There was no difference in CFQ or GDS 
depression scores between participants with and without airway obstruction (p > 0.05) in the whole 
sample. Next, we evaluated the effect of stressful life events on GDS, CFQ, MMSE, SF-36 PCS and 
MCS scores by subgroups of participants with and without airway obstruction. As shown in Table 13, 
two-way ANCOVA showed significant main effects of stressful life events for GDS (F = 64.500, df 
= 1, p < 0.001), SF-36 PCS (F = 7.054, df = 1, p = 0.008) and MCS (F = 14.710, df = 1, p < 0.001) 
scores. Significant interactions of stressful life events with airway obstruction were found for 
variables of GDS (F = 10.970, df = 1, p = 0.001), SF-36 PCS (F = 4.055, df = 1, p = 0.045), and 
MCS (F = 4.538, df = 1, p = 0.034) scores. The simple effects of stressful life events on GDS, SF-36 
PCS and MCS are shown for participants with and without airway obstruction respectively in Figure 
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5. Higher stress score was associated with higher GDS score, lower SF-36 PCS and MCS scores in 
participants with airway obstruction, more than in those without airway obstruction after adjusting 
for potential confounders, indicating the association of stressful life events with more psychological 
symptoms and poor QoL among individuals with airway obstruction, in comparison to non- airway 
obstructive individuals. The other significant main effect observed was of airway obstruction for 
decreased post-bronchodilator FEV1 (F = 17.458, df = 1, p < 0.001) and higher CFQ scores (F = 
5.424, df = 1, p < 0.05) after adjustment of sex, age, ethnicity, smoking status, and number of chronic 




         Table 12. Socio-demographic, pulmonary and psychological variables of study                    
participants aged 65 or older (Singapore Longitudinal Aging Study, SLAS-2) 
 Airway Obstruction  Non- Airway 
Obstruction 
Significant Test p 
 n  %  n  % 
        
Total 136 32.9  277 67.1   
        
Sex         
   Male 58 42.6  112 40.7 χ2  = 0.138, df = 1 0.710 
   Female 78 57.4  163 59.3   
        
Age (years, M±SD) 73.19 ±5.87  71.23 ±5.47 t = 3.328 0.001 
        
Ethnicity        
  Chinese 121 89.0  241 87.6 χ2 = 0.154, df = 1 0.694 
  Non-Chinese 15 11.0  34 12.4   
        
        
Smoking        
   Never smoker 77 57.6  211 77.3 χ2  = 20.59, df = 3 <0.001 
   Past smoker 29 21.6  41 15.0   
   Current smoker < 10 cigarettes daily 18 13.4  12 4.4   
   Current smoker ≥ 10 cigarettes daily 10 7.5  9 3.3   
        
Number of chronic diseases 2.60 ±1.30  1.65 1.25 t = 7.096 <0.001 
        
Number of Stressful Life Events 0.67 ±0.98  0.74 ±1.11 t = 0.609 0.543 
Stressful Life Event Score 1.02 ±1.71  1.12 ±1.78 t = 0.525 0.600 
        
Post-bronchodilator FEV1 1.42 ±0.50  1.75 ±0.52 t = 6.185 <0.001 
CFQ Score 38.0 ±9.21  38.8 ±9.83 t = 0.733 0.464 
MMSE Score 26.4 ±3.26  27.4 ±3.11 t = 3.090 0.002 
GDS Depression score 1.13 ±2.04  0.84 ±1.69 t = 1.487 0.138 
GDS ≥ 5, % (n) 5.2 (7)  2.9 (8) χ2  = 1.349, df = 1 0.245 
SF-36 PCS 44.6 ±9.04  47.1 ±7.21 t = 2.726 0.007 
SF-36 MCS 54.9 ±7.83  55.1 ±6.68 t = 0.353 0.724 
        
 
Figures in table denote mean ± SD or number and %. FEV1 = forced expiratory volume in the first second; CFQ = 
Cognitive Failure Questionnaire; MMSE = Mini-Mental State Examination; GDS = the Geriatric Depression Scale; SF-
36 = 36-Item Short-Form Healthy Survey; PCS = Physical Health Component Summary; MCS = Mental Health 
Component Summary.  
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Table 13. Two-way ANCOVA: stressful life events, airway obstruction and mental and physical variables 
 
  Main Effects of Airway 
Obstruction (df = 1) 
 Main Effects of Stress (df = 1)  Interaction (df = 1) 
  F p  F p  F p 
          
Post-bronchodilator FEV1  17.458 <0.001  0.323 0.570  2.057 0.152 
CFQ Score  5.424 0.020  1.927 0.166  2.514 0.114 
MMSE Score  1.799 0.181  1.159 0.282  0.380 0.538 
GDS Depression score  2.353 0.126  64.500 <0.001  10.970 0.001 
SF-36 PCS  0.432 0.512  7.054 0.008  4.055 0.045 
SF-36 MCS  0.659 0.417  14.710 <0.001  4.538 0.034 
 
              Adjusted variables: sex, age, ethnicity, smoking status, and number of chronic illness. FEV1 = forced expiratory volume in the first second; CFQ =    
              Cognitive Failure Questionnaire; MMSE = Mini-Mental State Examination; GDS = the Geriatric Depression Scale; SF-36 = 36-Item Short-Form  
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Figure 5. Stressful life events and mental and functional well-being among study participants with or without airway obstruction 




4.5 Study V: Stress, neuropeptide Y, and young adult asthma: a follow-up study 
Table 14 shows the baseline demographic, clinical, and psychological profiles of study participants 
aged 21-35 by acute asthma, stable asthma and the healthy control groups. There were no significant 
differences in mean age, proportions of gender and family housing conditions among the three 
groups (p > 0.05). Participants with acute asthma were more likely smokers (p < 0.001), to report 
poorer self-rated health status (p < 0.001), and have lower levels of lung function (FEV1 Pred and 
FVC Pred, p < 0.01). Compared to patients with stable asthma, patients with acute asthma had 
significantly longer mean duration of asthma history of 18.9 versus 15.1 years (p < 0.001); they did 
not have significantly more numbers of asthma attacks, but they were more frequently hospitalized in 
the last 12 months. Six (46.2%) patients in the acute asthma group and 20 (42.6%) patients in the 
stable asthma group reported taking medium to high dose of ICS (p = 0.82). Patients with acute 
asthma gave lower asthma control score (13.23 ± 5.12 vs. 18.86 ± 4.75, p < 0.001), and poorer 
asthma-related quality of life (3.94 ± 1.49 vs. 5.10 ± 1.35, p < 0.01). Asthma patients, especially 
those with acute asthma, reported higher levels of anxiety, depression, and neuroticism (a personality 
trait closely related to psychological distress). 57  
 
No significant difference in stressful life event score was observed among the three participant 
groups (164.14 ± 133.31 vs. 144.57 ± 101.72 vs. 139.39 ± 89.03, p > 0.05). However, notably higher 
scores of perceived stress were reported among respondents with acute asthma, than those reported 
by the healthy controls (21.43 ± 6.02 vs. 17.53 ± 6.20 vs. 16.58 ± 6.71, p < 0.05). They also had 
higher levels of ACTH (6.67 pmol/L vs. 4.12 pmol/L vs. 3.60 pmol/L, p < 0.05), noradrenaline 
(645.04  pg/ml vs. 498.8 pg/ml vs. 346.1 pg/ml, p < 0.001), adrenaline (99.6 pg/ml vs. 52.3 pg/ml vs. 
31.7 pg/ml, p < 0.001), and the HPA index (0.34 vs. -0.00 vs. -0.09 , p < 0.01) and lower levels of 
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cortisol (387.1 nmol/L vs. 389.4 nmol/L vs. 417.1 nmol/L, p < 0.01) than the healthy controls, 
indicating higher levels of stress and dysregulated HPA axis responsiveness in asthma patients. 
 
Respondents with asthma, especially acute asthma, had higher levels of Th2 cytokine IL-4 than 
healthy controls (6.96 pg/ml vs. 3.63 pg/ml vs. 1.57 ng/ml, p < 0.001), and lower levels of NPY (0.42 
ng/ml vs. 0.47 ng/ml vs. 0.62 ng/ml, p = 0.01). (Table 15) 
 
In the whole sample, baseline IL-4 level, controlling for age,  was significantly correlated with NPY 
(p < 0.05), ACTH (p < 0.01), noradrenaline (p < 0.05), adrenaline (p < 0.001), HPY index (p < 0.01), 
perceived stress (p < 0.05), anxiety (p < 0.05) and neuroticism (p < 0.05). Among healthy controls, 
IL-4 level was significantly correlated with noradrenaline (p = 0.01) and HPA index (p < 0.05). 
Among patients with acute asthma, but not chronic asthma, IL-4 was significantly correlated with 
adrenaline (p < 0.05), HPA index (p = 0.001), perceived stress (p < 0.05), and neuroticism (p = 0.01). 
IL-4 was not significantly correlated with NPY among patients with acute asthma, but was 
significantly correlated (p < 0.001) among patients with chronic asthma. Table 16. 
 
Among asthma patients, perceived stress (p < 0.05) and plasma NPY level (p < 0.001) in separate 
models (1 and 2) were individually significant predictors of IL-4 levels at baseline, controlling for 
gender, age, ethnicity, smoking status, family housing type, BMI, asthma severity, asthma control, 
and neuroticism. In the combination model that included both perceived stress and NPY (Model 3), 
only NPY remained a significant predictor of IL-4, whereas there was a reduction in the strength and 
significance of the association between perceived stress and IL-4. The Sobel test indicated that NPY 
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was a significant mediating variable in the relationship between perceived stress and baseline level 
(Z = 2.134, p < 0.05) of IL-4. In the biological stress model that assessed the HPA Index measure of 
biological stress, HPA index and NPY were also individually significant predictors of IL-4 levels in 
separate models, but in the combination model, both HPA index and NPY remained independently 
associated with IL4 levels. There was no suggestion from the Sobel test that NPY significantly 
mediated the relationship between HPA index and IL-4. 
 
Further analyses showed that perceived stress measured at baseline significantly predicted IL-4 level 
one year later, and this was not independent of NPY. The Sobel test indicated that NPY was a 
significant mediating variable (Z = 2.134, p < 0.05). HPA index at baseline, however, failed to 
predict IL-4 level one year later. In both analyses, NPY at baseline remained a significant 




Table 14. Socio-demographic, clinical, and psychological characteristics of young adults aged 21-35 years by 
acute asthma, chronic asthma, and healthy control 
 Acute Asthma 
(n = 19) 
Chronic Asthma 
(n = 51) 
Healthy Control 
(n = 69) 
Significance Tests 
F/ χ2/ t p 
      
Gender      
   Male 10 (52.6) 26 (51.0) 37 (53.6) 0.082 0.960 
   Female 9 (47.4) 25 (49.0)
 
 32 (46.4)   
Age 27.00 ± 4.89 27.27 ± 5.14 25.48 ± 3.38 2.800 0.064 
Housing type       
   1-3 room public housing 6 (40.0) 14 (27.5) 23 (33.3) 0.984 0.612 
   4-5 room public housing and others 9 (60.0) 37 (72.5) 46 (66.7)   
Smoking status      
   Non-smoker 6 (40.0) 35 (68.6) 65 (94.2) 26.216 <0.001 
   Past or current smoker 9 (60.0) 16 (31.4) 4 (5.8)   
Self-rated health      
   Very poor to fair to good 15 (93.8) 44 (86.3) 27 (39.1) 35.298 <0.001 
   Very good to excellent 1 (6.3) 7 (13.7) 42 (60.9)   
FEV1 2.04 ± 1.11* 2.79 ± 0.78 2.82 ± 1.03 3.043 0.051 
FEV1 Pred (%) 58.30 ± 25.64**+ 85.34 ± 21.73 87.21 ± 28.88 5.377 0.006 
FVC 2.76 ± 1.37 3.56 ± 1.02 3.70 ± 1.41 2.375 0.097 
FVC Pred (%) 67.20 ± 26.25**+ 90.34 ± 20.45 95.81 ±31.03 4.886 0.009 
Number of asthma attack within 1 year 4.44 ± 2.34 3.84 ± 5.87 NA 0.155 0.695 
Number of hospitalization past year) 1.81 ± 1.56 0.53 ± 0.95 NA 16.062 <0.001 
Duration of asthma (years) 18.87 ± 10.48 15.08 ± 10.19 NA 86.237 <0.001 
Dose of Inhaled corticosteroids (ICS)      
   Medium to high dose (≥250 μg/day) 6 (46.2) 20 (42.6) NA 0.390 0.823 
   Low dose (<250 μg/day) 2 (15.4) 11 (23.4) NA   
   No use 5 (38.5) 16 (34.0) NA   
Asthma control 13.23 ± 5.12 18.86 ± 4.75 NA 14.061 <0.001 
Asthma quality of life 3.94 ± 1.49 5.10 ± 1.35 NA 7.803 0.007 
   Activity limitation 1.97 ± 0.83 2.42 ± 0.64 NA 4.544 0.037 
   Symptom 3.74 ± 1.41 5.50 ± 1.48 NA 9.198 0.004 
   Emotional function 3.91 ± 1.72 5.01 ± 1.61 NA 5.258 0.025 
   Exposure 3.87 ± 1.51 5.05 ± 1.54 NA 6.873 0.011 
      
Stressful life events 164.14 ± 133.31 144.57 ± 101.72 139.39 ± 89.03 0.364 0.695 
Perceived stress 21.43 ± 6.02* 17.53 ± 6.20 16.58 ± 6.71 3.292 0.040 
Neuroticism 26.13 ± 8.16** 21.31 ± 6.99 19.16 ± 8.06 5.270 0.006 
Anxiety 9.13 ± 3.27* 7.47 ± 3.77 6.41 ± 3.54 3.944 0.022 
Depression 5.67 ± 3.48** 4.06 ± 2.81 3.26 ± 2.49 5.065 0.008 
      
Figures in table denote M ± SD or number and %. ** p < 0.01, * p < 0.05  vs. the healthy control group. + p < 0.05 







Table 15. Measurements of IL-4 and stress-related variables in young adults aged 21-35 years by acute 
asthma, chronic asthma, and healthy control 
 Acute Asthma 
(n = 19) 
Chronic Asthma 
(n = 51) 
Healthy Control 
(n = 69) 
Significance Tests 
F  p 
      
IL-4 (pg/ml) 6.96 ± 7.15*** 3.63 ± 6.79 1.57 ± 2.27 8.914 <0.001 
      
NPY (ng/ml) 0.42 ± 0.14* 0.47 ± 0.24* 0.62 ± 0.40 4.786 0.010 
      
Cortisol (nmol/L) 387.11 ± 130.63 389.44 ± 246.32* 517.10 ± 256.58 4.876 0.009 
ACTH (pmol/L) 6.67 ± 10.96* 4.12 ±3.55 3.60 ± 1.75 3.172 0.045 
Noradrenaline (pg/ml) 645.04 ± 329.46** 498.77 ± 413.41* 346.15 ± 179.90 8.615 <0.001 
Adrenaline (pg/ml) 99.64 ± 76.79***+++ 52.28 ± 43.92* 31.74 ± 18.51 20.889 <0.001 
HPA Index 0.34 ± 0.51* -0.00 ±0.59 -0.09 ± 0.37 5.984 0.003 
      
Data are presented as M ± SD. *** p < 0.001, ** p < 0.01, * p < 0.05 vs. the healthy control group. +++ p < 0.001 vs. 
the chronic asthma  group. IL-4 = interleukin 4, NPY = Neuropeptide Y, ACTH = adrenocorticotropic hormone. 
HPA stress index was created as a composite index of cortisol, noradrenaline, adrenaline and ACTH using principal 
component analysis score (percentage of cumulative covariance: 84.467%). 
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Table 16. Correlations of psychological and biological stress variables with IL-4 level 
 
 Whole sample  Healthy control  Chronic asthma  Acute asthma 
 r p  r p  r p  r p 
            
NPY 0.19 0036  0.24 0.054  0.61 <0.001  0.39 0.18 
ACTH  0.27 0.003  -0.14 0.26  -0.01 0.99  0.54 0.057 
Noradrenaline  0.20 0.027  -0.31 0.010  0.15 0.32  0.39 0.18 
Adrenaline  0.32 <0.001  -0.01 0.92  0.06 0.68  0.62 0.024 
Cortisol  -0.12 0.19  -0.12 0.35  -0.13 0.40  0.10 0.79 
HPA Index 0.23 0.007  -0.26 0.034  0.10 0.50  0.73 0.001 
Perceived stress 0.22 0.015  0.10 0.43  0.12 0.43  0.57 0.040 
              
All data are adjusted for age.  Adjusted for dosage of inhaled corticosteroid use (none, low dose (below 250 
μg/day), and medium to high dose (equal to or above 250 μg/day)) in whole sample and chronic and acute asthma 
group. NPY = Neuropeptide Y, ACTH = adrenocorticotropic hormone. HPA stress index was created as a composite 
index of cortisol, noradrenaline, adrenaline and ACTH using principal component analysis score (percentage of 




Table 17. Independent associations and mediational analyses of measures of perceived and HPA stress and NPY with IL-4 concentrations among patients with 
asthma 










 B SE β p 
Psychological stress models               
Model 1: Perceived stress 0.119 0.71 0.29 0.58 0.019   0.129 0.88 0.37 0.67 0.025   
Model 2: NPY   0.479 28.82 4.31 0.75 <0.001   0.534 32.89 4.70 0.81 <0.001   
Model 3: Perceived stress controlling for NPY 0.376 0.27 0.22 0.22 0.234 *   0.416 0.28 0.28 0.21 0.324 ‡   
                 NPY controlling for perceived stress 0.109 26.50 4.25 0.69 <0.001   0.146 29.75 4.70 0.74 <0.001   
               
Biological stress models               
Model 1: HPA index 0.085 3.49 1.43 0.29 0.018   0.052 2.75 1.72 0.23 0.115   
Model 2: NPY 0.205 14.62 3.60 0.45 <0.001   0.381 22.89 4.25 0.62 <0.001   
Model 3: HPA Index controlling for NPY 0.204 3.47 1.27 0.29 0.008   0.356 1.99 1.38 0.16 0.156   
                 NPY controlling for HPA 0.084 14.58 3.43 0.45 <0.001   0.027 22.24 4.23 0.60 <0.001   
               
                       * Sobel test: Z=2.134, p=0.033; ‡ Sobel test: z=2.143, p=0.032.  
Analyses in the Psychological Stress model were controlled for base model variables: age, gender, ethnicity, housing type, smoking status, body mass 
index (BMI), asthma severity, and asthma control score and neuroticism.  
R
2 
change is change in model R
2 
from base model upon addition of the candidate predictor variable. SE = standard error, NPY = Neuropeptide Y, ACTH = 
adrenocorticotropic hormone. HPA stress index was created as a composite index of cortisol, noradrenaline, adrenaline and ACTH using principal 
component analysis score (percentage of cumulative covariance: 84.467%). 
               
 




CHAPTER 5 DISCUSSION 
5.1 Study I: Prevalence of anxiety and depressive symptoms in adolescents with asthma: a 
meta-analysis and meta-regression 
5.1.1 Higher prevalence of depressive symptoms among adolescents with asthma 
There are approximately 300 million people worldwide suffering from asthma and annually 250,000 
deaths attributed to the disease. 213 Among children under 15 years, asthma is the third-ranking cause 
of hospitalization. 214 By 2020, depressive symptoms will rank the second cause of disability globally. 
215 Despite the abundance of literature reporting data on these two conditions, only eight studies met 
the inclusion criteria of this meta-analysis and this reflects the paucity of high-quality studies which 
examine the prevalence of depressive symptoms in adolescent asthma.  
 
This study is, to our knowledge, the first meta-analysis aiming to estimate the aggregate prevalence 
of depressive and anxiety symptoms in adolescents with asthma compared with the healthy controls. 
The aggregate prevalence of depressive symptoms in adolescents with asthma was 27.0%, suggesting 
that at least one in four adolescents with asthma may experience depressive symptoms. Moreover, 
the aggregate prevalence of depressive symptoms was twice as high in adolescents with asthma as in 
the healthy controls. These findings suggest that asthma may be a risk factor for depressive 
symptoms in adolescents and this is hardly surprising as asthma affects daily functions that would 
require physical activity such as ambulation, mobility and school activities and psychosocial 
functioning. 95 However, the relationship between asthma and depression could be on the other way. 





The current meta-regression demonstrated that proportions of Caucasian and smokers significantly 
increased the heterogeneity; whereas age, gender, and severity of asthma were not significant 
moderators. Smoking has long been considered a risk factor for anxiety and depressive symptoms. 
216-218 Higher likelihood of frequent nocturnal coughing and breathing problems in smokers were 
reported in adolescent studies. 219, 220 Although the National Heart Lung and Blood Institute (NHLBI) 
recommends that persons with asthma should not smoke or be exposed to tobacco smoke in their 
environment, studies have found that the prevalence of smoking among those with asthma is the 
same as of those without asthma, or in some instances higher. 221-223 The higher prevalence of 
smoking can be explained by the self-medication hypothesis, 224 which describes the use of tobacco, 
drugs or other self-soothing forms of behavior to treat untreated and often undiagnosed mental 
distress, stress and anxiety. 225-227 This is often seen as a struggle to gain personal independence from 
conventional medical treatment. 228 Specifically, smoking may function as a compensatory means to 
modulate effects and treat distressful psychological states, whereby individuals with asthma may 
choose it to manage their depressive and anxiety symptoms and help them achieve emotional stability. 
229, 230 As a potential confounder, stressful life events encountered by adolescents can independently 
affect the course of asthma while adolescents with asthma tend to cope with stressful life events by 
smoking. 231  
 
Consistent with other multi-ethnicity reports, 232-234 our analysis revealed the variability of prevalence 
of depressive symptoms in different ethnicities. Higher rates of depressive symptoms among 
Caucasians may reflect a tendency of them to express psychological distress compared with other 
ethnicities. 234 Furthermore, Caucasians generally tend to have higher socioeconomic status and more 




utilization such as insurance, time, and transportation compared with the ethnic minorities. 235-237  
 
In this meta-analysis, severity of asthma was not a significant moderator in explaining the 
heterogeneity of calculating the OR of depressive symptoms among adolescents with asthma versus 
the healthy controls. This is consistent with studies indicating that anxiety and depressive symptoms 
in asthma patients may be independent of the severity of asthma. 238, 239 It may be the presence of 
asthma, but not the severity of the disease, which is associated with the comorbidities of 
psychological distress. 
 
5.1.2 Higher prevalence of anxiety symptoms among adolescents with asthma  
In this meta-analysis, it is noticeable that adolescents with asthma have higher risk (OR = 1.83) to 
develop anxiety symptoms and this finding is congruent with previous studies. 240-242 Several theories 
are proposed to explain the elevated risk for anxiety symptoms especially panic disorder among 
asthma patients. The biological and behavioral theories indicate that repetitive experience with 
hypoxia and hypercapnia in asthma attack may sensitize the amygdala and locus coeruleus and leads 
to overreaction to subsequent episodes of asthma attacks as a result of classical conditioning by 
pairing conditioned stimuli (i.e. sensation of breathlessness) and conditioned response (i.e. fear and 
anxiety). 228, 229 The cognitive theory suggests that the unpredictable and longitudinal experience with 
asthma attacks may generate fearful or catastrophic beliefs which provoke panic attacks and 
anticipatory anxiety. 228, 243 Children with anxiety disorders report more somatic symptom during 
inhalation of CO2-enriched air compared with children without anxiety disorder. 230, 244 Furthermore, 





The impact of depressive and anxiety symptoms in patients with asthma is an important research area 
as it may be related to disease control and prognosis. 246 Alexander et al. (1972) and Weingarten et al. 
(1985) measured the effect of relaxation therapy on peak expiratory flow of asthmatic children and 
found effects favoring the treatment group compared with the control group. 247, 248 Brown et al. 
(2005) performed a randomized controlled trial by comparing the effects of citalopram, a selective 
serotonin reuptake inhibitor and placebo in asthma patients with depressive symptoms, 249 and found 
that antidepressant-treated patients required fewer oral corticosteroids than the placebo group. 
Furthermore, there is a lack of studies to draw conclusions regarding the utility of psychological 
approaches for improving asthma-related outcome. There is still a considerable need for good quality 
prospective studies to continue investigation into the causality and temporal relationship between 
asthma and depressive and anxiety symptoms and response to treatment. 
 
The strength of this meta-analysis includes meta-regression and subgroup effect size analyses. 
Majority of the studies (seven out of eight) involved asthma patients from communities with 
relatively large sample size or population-based study designs, and this reflected the true prevalence 
in primary care which is largely free of clinical selection bias. Hence, our findings are more relevant 
to family physicians and public health policy makers in formulating strategies to reduce the burden of 
depressive and anxiety symptoms among adolescents with asthma in the community. 250, 251 
 
There are a few limitations in the current meta-analysis. The major limitation is that depressive and 




by doctors. Hence, the results of this study refer to the aggregate prevalence of depressive symptoms 
rather than depressive disorder. This study examined the cross-sectional data or the baseline data of 
cohort studies which cannot determine the causation or temporality of the association between 
psychological symptoms and adolescent asthma. Another limitation of the current study is the small 
number of studies involved, although the number of participants was reasonable (3,546 adolescent 
asthma patients and 24,884 healthy adolescent controls). We have considered only a small number of 
demographic and disease-related moderators in the meta-regression analysis due to the limited 
number of studies.  
 
In conclusion, adolescents with asthma are in a higher risk to develop depression and anxiety. Family 
doctors, pediatricians and healthcare providers should formulate strategies to detect depressive and 
anxiety symptoms in adolescents with asthma and offer psychological interventions to reduce the 
burden of psychiatric comorbidity. 
 
5.2 Study II: Asthma control, perceived stress, and quality of life in adolescents with asthma: a 
case-control study 
In this study, we found higher levels of depression, panic attacks, total anxiety and total internalizing 
symptoms among adolescents with asthma when compared to the healthy controls. Our findings 
further support the association between adolescent asthma and psychiatric comorbidities that have 
been reported from previous studies. 252 The results from this study revealed no associations between 
social phobia, separation anxiety and adolescent asthma, whereas previous studies have reported 





Among psychiatric comorbidities, the scores of panic symptoms and number of participants reaching 
clinical threshold of severe panic symptoms appeared to be highest, particularly for adolescents with 
poorly controlled asthma. This finding is consistent with previous studies. 254 Studies that carefully 
discriminated between symptoms of panic attacks and asthma attacks 255 have supported the observed 
excess comorbidity of panic attacks in asthma patients. 227 Patients with panic disorder were reported 
to have a three times higher risk of respiratory illnesses (such as asthma, bronchitis and emphysema) 
in comparison to patients with other psychiatric illnesses. 256 Nevertheless, further investigation is 
required before a conclusion of the relationship between asthma and panic attacks is drawn. 
 
In this study, adolescents with asthma had not only more severe psychiatric comorbidities but also 
higher frequencies of socio-demographic variables that are known to be associated with both asthma 
and psychiatric comorbidities. Higher proportions of Malay and Indian ethnicities, past history of 
smoking, higher BMI and lower housing status were more common among adolescents with asthma, 
especially those with poorly controlled asthma as compared to the healthy controls. This finding is 
consistent with previous studies of the association of socio-demographic factors and smoking with 
asthma and depression. Previous reports have also shown that higher body weight and BMI were 
associated with relapse and more severe depressive and anxiety symptoms in asthma patients. 257  
 
The present study extends previous research findings by examining the major psychological factor of 
perceived stress, as a contributor to the observed excess of psychiatric comorbidities associated with 




healthy controls. No significant differences in psychiatric comorbidities were observed after allowing 
for differences in this psychological factor. The results of a high level of perceived stress in patients 
with asthma in this study are consistent with the findings from previous studies. 253 In population-
based studies, stressful life events were reported to be associated with an increased risk of asthma-
related hospital admissions, 104 but daily hassles did not predict the onset of asthma. 150 In adults with 
asthma, 258 several types of stress were found not associated with asthma morbidity, but early 
traumatic life events predicted adult asthma onset. 259 A meta-analysis concluded that exposure to 
stressors alone does not increase the risk of allergic disorders, but only exposure to stressors which 
evoke negative cognition leads to an adverse impact on asthma patients. 61 These findings highlighted 
the importance of individual variation in perception of stress, and the importance of perceived stress 
in the course of asthma. Recurrent and unpredictable asthma attacks in poorly controlled asthma may 
cause patients to perceive high levels of stress, leading to psychiatric comorbidities. 
 
Furthermore, the findings from this study showed that poor asthma control was associated with 
severe psychiatric comorbidities. This is consistent with previous findings that comorbid anxiety and 
depression among asthma patients were associated with more days of asthma symptoms, 95 poor 
treatment adherence and greater functional impairment. 202 The association between the level of 
asthma control and psychiatric symptoms was not significant after accounting for perceived stress, 
indicating the significance of perceived stress in the control of asthma symptoms and psychiatric 
comorbidities. 
 




asthma by pediatricians, thus enhancing clinical accuracy and reducing symptom association bias. 156 
We adjusted for important confounding by socio-demographic and smoking variables 202 in 
multivariate analyses. The healthy controls were age- and gender-matched adolescents residing in the 
same community with the patients, which ensures good comparability between the two groups. A 
major limitation of the study is that causal inferences cannot be determined from this cross-sectional 
study. Further longitudinal studies are required to examine the relationship between stress, asthma 
and psychiatric comorbidities. Because measures of psychiatric comorbidities and stress were based 
on self-reports, possible bias from differential recall and social desirability cannot be ruled out. 
 
In conclusion, the presence of asthma and poor asthma control in adolescents are associated with 
psychiatric comorbidity, especially depression, panic attack, total anxiety and total internalizing 
symptoms. Perceived stress contributes to the observed excess psychiatric comorbidity associated 
with asthma, especially in poorly controlled asthma patients. Psychological therapy and support for 
asthmatics with high perceived stress should be integral in the management of asthma. 
 
5.3 Study III: Asthma, psychological stress and psychiatric comorbidity: a population-based 
study in adult Singaporeans 
Our study supports previous published findings of the strong association of asthma and other chronic 
physical conditions with psychiatric disorders and impaired QoL. About 14.2% of individuals with 






Interestingly, in this study of Asian adults, asthma was found to be more evidently associated with 
depression than with anxiety disorder. Although some studies have reported higher rates of 
depressive symptoms in individuals with asthma, 207, 260, 261 there were negative findings as well. 18, 93 
On the other hand, clinical and epidemiological studies typically involving children, adolescents and 
young adults have emphasized higher rates of anxiety disorders such as panic attacks in asthma cases, 
when compared to their non-asthmatic counterparts or those who had other chronic physical 
conditions. 18, 262-264 In many studies using symptom scales, it may be difficult to distinguish 
perceived symptoms that could be misinterpreted as both asthma/dyspnea and anxiety 
symptoms/panic disorder. This study used a standardized and well-validated diagnostic interview to 
assess a range of common psychiatric disorders and the results showed notably lower prevalence of 
GAD. Furthermore, in this community-based study, the results are less likely to be influenced by 
selection bias associated with help-seeking by anxious patients in studies in clinical settings.  
 
We observed in this study that while psychiatric disorders were nearly equally more common in 
individuals with asthma and those with other chronic physical conditions, excessive stressful life 
events were four times more frequent in respondents with asthma compared to those with other 
chronic physical conditions. As a known risk factor for psychiatric disorders, an excess of stressful 
life events appeared to mediate the observed comorbidity of psychiatric disorders in asthma, more 
than in other chronic physical conditions in this cross-sectional study. Extensive literature 12, 265 has 
described the stress and anxiety provoked by breathing difficulties/dyspnea, including muddled 
thoughts, heightened emotions, extreme fear and panic and decreased physical energy. Recent studies 
indicate that patients with asthma attacks and anaphylaxis had an excess of PTSD symptoms and 




depression. 266, 267 Although empirical evidence is still limited, there are also reports of an increase in 
asthma exacerbations in children immediately following a stressful life event. 268 There is also 
intriguing evidence suggesting that negative emotions such as sad mood or anxiety produce 
respiratory effects that are consistent with airway instability or asthma exacerbations. 269 This 
relationship is biologically plausible in terms of the down-regulation of the normal stress response 
pathways in the HPA axis and the SAM system, which in turn alters cytokine profiles favoring 
allergic inflammation. 270 Further research is required on this mutual relationship between asthma and 
response to stressors and coexisting psychiatric disorders.   
 
Our finding of worse QoL among individuals with asthma compared to those without chronic 
physical conditions was expected and is well established. 271, 272 Among individuals with asthma, 
studies also suggest that the co-occurrence of psychiatric disorders significantly affects performance 
of daily activities and use of health care services. 273, 274 In the present study, we found that QoL was 
more impaired in individuals with asthma compared to individuals with other physical conditions as 
well; furthermore, stressful life events made large contributions (R2 = 0.16) to the observed 
differences in impaired QoL, whereas diagnoses of depression and anxiety disorders contributed less 
(model R2 = 0.03 to 0.11). This suggests that in community-based settings, addressing stress and 
psychological disturbance beyond the clinical diagnosis of mental disorders is likely to make 
considerable impact in alleviating poor QoL in individuals with asthma.   
 
The strengths of the present study include the population-based design and large sample size. The 




controlled for important confounding by demographic and psychosocial variables in the analysis. 
While most studies have investigated psychological symptoms, the present study used a standardized 
and well-validated diagnostic interview to assess a range of common mental disorders. There are 
several limitations in this study. The case definition for asthma based on self-report is not ideal. 
However, studies have indicated that patients’ self-reports of most chronic diseases which are largely 
symptoms-based diagnoses such as asthma, are generally accurate. 275, 276 To minimize ascertainment 
errors, we asked subjects to allow inspection of their asthma medications. Misclassification errors 
were also likely to result from unrecognized or untreated illnesses, or screen-negative cases of 
psychiatric disorders. Missing values on LTEQ for a small number of items and study participants 
may also affect the accuracy of our results. Finally, firm causal inferences cannot be made from the 
cross-sectional findings in this study.  
 
In conclusion, coexisting psychiatric disorders are more likely to be observed in individuals with 
asthma or other chronic physical conditions, compared to those without chronic physical conditions. 
However, an excess of stressful life events is more common in individuals with asthma, and mediates 
the association of asthma and psychiatric disorder and contributes to impaired QoL. These 
relationships should be further investigated in future longitudinal studies.  
 
5.4 Study IV: The impact of stressful life events on quality of life in the elderly with airway 
obstruction 
The principal finding in this study indicated that stressful life events were associated with depressive 




but showed a significantly stronger association among individuals with airway obstruction than those 
without airway obstruction (interaction), suggesting a disproportionately greater detrimental effect of 
stressful life events on airway obstruction. To our knowledge, no other studies have reported 
demonstrating this relationship.  
 
It should be noted that participants with airway obstruction actually did not report greater frequency 
of occurrence or perceived stress score of non-illness related life events than non- airway obstructive 
participants. Instead, individuals with airway obstruction appeared to experience the same number of 
non-illness related life events and perceived them to be equally stressful as their non- airway 
obstructive counterparts, yet showed disproportionately greater psychological distress and poorer 
QoL. These results suggest that individuals with airway obstruction may be more vulnerable to the 
adverse impact of stressful life events than non- airway obstructive individuals. This may be due to 
different perception and appraisement of stressful life events, or poorer coping skills and fewer social 
and economic resources in individuals with airway obstruction, or both. We did not measure 
cognitive appraisal, coping resources and social support to explore these hypotheses directly, and this 
is a limitation of our study.  
 
There are few studies that have investigated the relationship between cognitive appraisal of stressful 
life events, coping strategies and psychological distress in individuals with airway obstruction. A 
study by Andrenas et al. 64 assessed how hospitalized patients with acutely exacerbated COPD 
appraised and coped with a recent stressful life events and their level of psychological distress. They 




threat, 26% as harmful, 7.6% as a loss, 4.3% as a challenge, and 11% characterized the stressful 
event in some other ways. However, the authors failed to find any association of psychological 
distress with types of stressful life events, stress intensity, primary or secondary appraisal, or number 
of coping strategies used. Only problem-solving coping strategies were inversely correlated to 
psychological distress. This suggests that poor coping skills may be the principal psychological 
problem among COPD patients that contribute to their psychological distress and poor QoL. Further 
studies are required to investigate the psychological characteristics of individuals with airway 
obstruction.  
 
Our secondary finding of the main effects of airway obstruction on FEV1 was expected and thus not 
surprising. However, the association of airway obstruction with more frequent cognitive problems 
was interesting, although the results for MMSE score were not significant after adjustment in two-
way ANCOVA, possibly due to sample size limitation. These results are consistent with clinical and 
population studies that indicate the impact of chronic airway obstruction on deficits in abstract 
reasoning, 277 complex visual motor process, 278 verbal learning, 279 language, 280 attention, 281 
information processing speed, 281-283 verbal learning and memory 282, 283.  
 
The present study has strengths and limitations. The case definition for airway obstruction is 
accurately based on post-bronchial dilatation spirometric measures of chronic airflow obstruction 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommended 
criteria. The measure of life event stress is modified to exclude illness-related stress from chronic 




events and cross-sectional study design hinder precise assessment of stressful life events and 
interpretation of a causal relationship between stress and health-related functional outcomes. 
 
Studies 8-10 have reported that mental health status, including anxiety and depressive symptoms, are 
better predictors of chronic airway obstruction-related QoL than pulmonary function. The present 
study supports this observation and further indicates that stressful life events have a starkly 
detrimental effect on mental health and QoL in individuals with airway obstruction. More studies of 
the effects of stress management and coping strategy in psychological interventions in airway 
obstruction should be investigated in randomized controlled clinical trials. It is increasingly being 
recognized that the identification of mood and anxiety disorders, and psychological and psychosocial 
interventions to improve mood and reduce anxiety are important for improving patient centered 
outcomes in chronic airway obstructive patients. However, in published clinical guidelines, where the 
initial step care management by practitioners in primary care and general hospital settings includes 
low-intensity psychosocial interventions for patients with persistent subthreshold depressive 
symptoms or mild to moderate depression, there appears to be little attention given to identifying 
stressful life event(s) and supporting chronic airway obstructive patients experiencing stressful life 
events to prevent the onset of mood and anxiety disorders. In particular, group-based peer support, 
individual guided self-help based on cognitive behavioral therapy (CBT) principles or computerised 
CBT to reduce patients’ vulnerability to stress may usefully include objective cognitive appraisal of 
stress, problem-solving coping skills, and relaxation therapy to help support chronic airway 





In conclusion, this study found that stressful life events were associated with more depressive 
symptoms and worse QoL in individuals with airway obstruction, much more than in those without 
airway obstruction. Further studies should explore the role of cognitive appraisal of stress, coping 
resources and psycho-social support in this relationship.  
 
5.5 Study V: Stress, neuropeptide Y, and young adult asthma: a follow-up study 
Psychological stress and asthma In the present study, we found that although exposure to stressful 
life events did not differ among groups, asthma patients, especially those with acute asthma, 
experienced higher levels of perceived stress than their healthy control counterparts. The high levels 
of perceived stress in asthma patients were corroborated by higher levels of ACTH, noradrenaline, 
adrenaline, and the HPA index, and lower levels of NPY and cortisol, compared with healthy 
controls. Furthermore, perceived stress predicted elevated levels of IL-4, which is important in the 
physiopathology of Th1/ Th2 imbalance 284 in asthma. This is consistent with previous research 
documenting the strong link between psychological stress and asthma. Studies suggest that traumatic 
life events in early childhood predict subsequent asthma onset 259 and stressful life events such as a 
death in the family and mourning have been shown to trigger the first attack of asthma, 63 an increase 
in the risk of new onset asthma, 59 or asthma-related hospital admissions. 104 Perceived stress is 
reported to be associated with increased asthma incidence, daily medication intake and first-time 
hospitalization risk. 55, 61 
 
Psychological stress, HPA activation and cortisol Although a disruption in neuroendocrine-immune 




effects of psychological stress, 74 the specific mechanism underlying the association between 
psychological stress and asthma is not well elucidated. Our results showed that among the patients 
with asthma, the elevated peripheral levels of ACTH, noradrenaline and adrenaline, and HPA index 
indicate stress-induced activation of the HPA axis and adrenal medulla in asthma. Studies have 
shown that bronchoconstriction is not a stimulus for sympatho-adrenal activation, 285 hence the 
observed activated HPA stress response was most probably due to psychological stress rather than 
airway disorder. The concurrent low levels of cortisol observed in asthma patients is consistent with 
studies which observed a marked rise in ACTH concentrations with no concomitant increments or 
markedly diminished cortisol concentrations, 286, 287 indicating a dampened cortisol response related 
to a disturbance in stress-induced HPA activation. Chronic stress is thought to result in adaptive 
mechanisms of glucocorticoid receptors in the form of increased negative feedback sensitivity, hence 
leading to lower cortisol secretion. 288 
  
Psychological stress and NPY Studies of U.S. army soldiers participating in survival training indicate 
that under normal conditions, acute stress elicits NPY release and that this release is positively 
associated with cortisol and NE release; greater levels of NPY release are associated with less 
psychological distress, suggesting that NPY confers anxiolytic activity. 289 The anxiolytic effect of 
NPY under physiological conditions is supported by animal studies in which intracerebroventricular 
administration of NPY in rats reduced social (intruder) stress as measured by significant decrease in 
blood pressure, heart rate, and activity. 290 On the other hand, under chronic conditions of prolonged 
stress, combat veterans with PTSD compared to healthy individuals are documented to exhibit both 
lower NPY and cortisol levels in plasma, and evidence of increased anxiety and sympathetic system 




greater symptoms of PTSD, and levels of norepinephrine and systolic blood pressure induced by a 
noradrenergic α2-antagonist, yohimbine, suggesting a dampened NPY response. 291, 292 Our results of 
lower levels of NPY and cortisol and higher levels of ACTH, adrenaline and noradrenaline in 
patients with chronic asthma, both non-exacerbated and acutely exacerbated, than the healthy 
controls are in concordance with these prior findings supporting the effect of chronic stress exposure 
in blunting NPY responsiveness 293 with associated dysregulation of the sympathetic nervous system.  
 
Asthma and IL-4 The pathogenesis of asthma is widely believed to involve airway inflammatory 
response mediated by CD4+ T cells with a bias toward Th2 responses in the balance between Th1 
and Th2 responses. 294 IL-4 is a key Th2 cytokine and an essential cofactor for IgE production that 
triggers a humoral immune response toward up-regulation of IgE, a prototypic feature of allergies. 284, 
295 The release of IL-4 is thus a key marker of allergic inflammation that correlates well with asthma 
severity. 296, 297 Higher levels of IL-4 are reported in children with both controlled and uncontrolled 
asthma than healthy controls. 298, 299 Furthermore, increased levels of IL-4 are reported to be 
associated with acute stress events among children with asthma and chronic family stress. 300 Our 
observation of higher circulating levels of IL-4 among asthma patients especially those with acute 
exacerbations are in agreement with previous reports. 298, 299 
 
Psychological stress, IL-4 and NPY mediation in asthma Stress is believed to alter immune response 
features of asthma which involve a bias away from cellular (Th1) immunity and towards humoral 
(Th2) immunity, typically manifested by the over-expression of Th2 cytokines and manifested in 




of chronic stress showed increased production of IL-4 in response to acute stress. 300 We replicated 
this finding among the patient groups with non-exacerbated and acutely exacerbated chronic asthma 
in this study. We further found that perceived stress among asthma patients was a significant 
predictor of IL-4 levels measured both concurrently at baseline and one year later; suggesting that 
perceived stress has a persistent effect in heightening Th2 immune and inflammatory responses in 
asthma. We further extend this finding by providing a plausible biological mechanism for the 
influence of perceived stress on the immune-inflammatory profile in asthma. Our data strongly 
suggests that plasma levels of NPY mediated the association of high perceived stress levels with  the 
over-expression of IL-4 in asthma. 
 
We also explored the HPA index as an integrated measure of the body’s systemic HPA and SAM-
related response to a totality of internal biological stressors, and its effect on the levels of Th2-
associated IL-4 expression in asthma. In like manner, the results indicated that a heightened level of 
HPA activity was associated with elevated levels of IL-4 in asthma. In keeping with its temporal 
measurement of acute stress response, the HPA index did not predict IL-4 levels at one-year follow 
up. NPY level did not appear to mediate this relationship. Our data suggest that NPY concentration is 
a steady state measure of neuroendocrine activity, and consistently and independently predicted a 
long-lasting Th2-associated hyper-immune and inflammatory response in asthma. 
 
NPY and IL-4 in asthma The relationship between NPY and IL-4 in asthma is not well understood. 
Biological studies have yielded controversial and ambiguous findings, 303, 304 and reports of human 




cell priming, but paradoxically it acts as a negative regulator for T cells and modulates T cell hyper-
responsiveness, thus suggesting a bimodal role in APCs and T cells in the immune system. 303, 305, 306 
Studies in mice models of asthma suggest that NPY was elevated at the late (chronic) stage of the 
airway inflammatory process, and was inversely correlated with the level of IL-4, suggesting an 
effect in attenuating Th2 cytokine production and release. 307 It remains unclear whether the increase 
in NPY is a defensive or compensatory mechanism to modulate the effects of inflammatory 
cytokines. A limited number of human studies have yielded equivocal findings. Among young 
asthma patients, plasma concentrations of NPY measured before and during bronchoconstriction 
induced by histamine or allergens remained unchanged up to 30 minutes after bronchoconstriction. 
285 Another study showed that children with mild asthma and healthy controls reportedly did not 
show any differences in NPY levels. 302 A study of elderly patients with acute asthma attacks in an 
emergency medicine ward reported elevated plasma concentration of NPY, but notably the authors 
concluded that circulating NPY under these conditions more likely had a nervous rather than adrenal 
origin. 301 Our study showed that NPY levels, consistent with a dampened response associated with 
chronic psychological stress, were lower among acutely exacerbated and non-exacerbated asthma 
patients, compared to healthy controls. However, among asthma patients, an elevated level of NPY 
was found to be associated with a persistent elevation of IL-4 which is a prominent marker of Th2-
biased immune and inflammatory profiles. This paradoxical association may possibly reflect 
increased NPY-ergic activity in response to high IL-4 in asthma. Given the role of NPY in the neural 
control of immune responses, increased secretions of NPY in the late stage of the airway 
inflammatory process normally acts to attenuate Th2 cytokines production and release in asthma. 





Our findings are important since they add new insights into the psychobiological mechanisms 
underlying the relationships between psychological stress and asthma. However, there are limitations 
to this study. The cross-sectional design of the study makes it difficult to interpret the temporal 
causal relationship especially between NPY and IL-4. The present study used peripheral and not 
central measures of NPY to assess neuroendocrine responses to stress. Studies have shown that 
cerebrospinal fluid (CSF) levels of NPY are approximately three times higher than plasma levels of 
NPY, and the correlation between plasma NPY and CSF NPY is weak (r = 0.29). 308 Although 
evidence suggests strikingly similar response patterns of central and peripheral NPY to stress, 309 
future brain imaging research using specific NPY-receptor ligands would be helpful to address the 
relationship between central release of NPY and psychological and immune functions. Another 
limitation is that the atopic status of the asthma patients in the study was not characterized. The 
relatively small sample size from this study may have limited the power of the study to detect 





CHAPTER 6 SUMMARY AND CONCLUSION 
In a series of studies (Study I to Study V), this thesis investigated the contribution of psychological 
stress to the psychiatric comorbidities and functioning impairment observed in obstructive airway 
diseases in adolescent, adult and elderly individuals. Among young adults who are free from 
comorbidity with other respiratory diseases, we assessed the potential mediating role of NPY in the 
association between perceived stress and asthma. 
 
Results of the present thesis supported our hypothesis of a pivotal role of psychological stress, 
assessed in this study as stressful life events and perceived stress, in the close association of 
psychological symptoms and obstructive airway diseases. Asthma was associated with higher levels 
of depression, panic attacks, total anxiety and total internalizing symptoms in adolescents, and a 
higher prevalence of any psychiatric disorder, major depressive disorder and generalized anxiety 
disorder among adults. Participants with asthma, especially those with poorly controlled asthma, 
reported significantly lower quality of life scores. Meanwhile, higher levels of perceived stress were 
found in adolescents and young adults with asthma compared to the healthy controls, and among 
poorly controlled asthma patients and patients with acute exacerbations. The mean stressful life event 
score in adults with asthma was approximately 3 times as high as in adults with other chronic 
medical conditions and 5 times as high as in the healthy controls. Furthermore, stressful life events 
and perceived stress contributed, to a great extent in hierarchical regression models, to the psychiatric 
comorbidity and impaired quality of life among adolescents and adults with asthma. In the elderly, 
stressful life events were found to be associated with more depressive symptoms and worse physical 
and mental functioning in respondents with airway obstruction than in those without airway 





The neuroendocrine and immune physiology underlying the association of psychological stress and 
asthma is not well studied in humans. The present thesis investigated the association of measures of 
psychological and biological stress with Th2 expression of IL-4 and the mediating role of NPY in 
this association among young adults with acute and stable chronic asthma and their age- and gender-
matched controls. Asthma was associated with higher levels of psychological stress, corroborated by 
elevated levels of HPA-related levels of ACTH, NA, A, and depressed levels of cortisol and NPY, 
reflecting blunted adaptive responses to chronic stress. Higher levels of perceived stress were further 
shown to be associated with increased levels of IL-4 among the asthma patients. The precipitating 
effect of perceived stress on IL-4 was mediated by the levels of NPY, and this relationship might be 
lasting by observing their associations with a repeat measure of IL-4 levels at follow up one year 
later. The HPA index measure of transient biological stress, independent of NPY, was a significant 
predictor of IL-4 at baseline but not at one-year follow up. These findings confirm our hypothesis of 
a pivotal role of NPY in the association between psychological stress and asthma. More studies are 
required to elucidate its immune-modulatory role in asthma.    
 
The current study investigated the relationship between psychological (stress, depression and 
anxiety), immunological (inflammatory cytokines) and neuro-endocrine and humoral (NPY, ACTH, 
cortisol, adrenaline, noradrenaline, HPA stress index) status of individuals with airway obstruction 
(well controlled and poorly controlled, with acute exacerbation and in the quiescent state) and 
healthy controls and results emphasized the role of stress in the severity, symptom control, 
psychological health and quality of life of individuals with obstructive airway diseases, which may 




psycho-neuro-immunological perspective might be helpful to enhance, to some extent, the 
understanding of the link between stress and airway obstruction and the inter-individual variation in 
response to stress and airway obstruction in adolescent, adult and elderly individuals. In view of our 
findings, treatment and control of asthma and airway obstruction should seriously consider the excess 
rates of comorbid depression and anxiety, which is particularly high in patients with acute 
exacerbations or poorly controlled asthma. High levels of perceived stress are key vulnerability 
factors for comorbid psychiatric comorbidity, and it is advisable to screen patients for psychological 
treatment. CBT can target cognitive bias such as the tendency to overestimate stress and negative 
experience. Relaxation therapy, as well as peer group support among patients with airway obstruction, 
may be included to reduce the risks of panic attacks, negative emotions and stress levels. The 
significance of NPY as a “resilience factor” in modulating stress exposure and asthma morbidity 
supports the recently proposed use of NPY agonists 310 in treating stress-exacerbated asthma which 
represents a psychosomatic approach in pharmacological therapy of asthma and other psychosomatic 
disorders. To confirm the potential benefits of NPY agonists in stress modulation, randomized 
controlled trials targeting the high-risk population (for example, those with low NPY and high 
perceived stress) could be performed in the future. 
 
The findings from this study should be interpreted with caution because of multiple limitations. 
Potential bias from differential recall and social desirability could not be ruled out because quite a 
number of measurements in this study (such as anxiety and depression, QoL and perceived stress) 
were based on self-reported questionnaires. Given the time constraint of a PhD thesis, our studies had 
either cross-sectional (Study II-Study IV) or relatively short follow-up (Study V) study designs. 




examined the role of NPY in resilience to stress, the interval between baseline and follow-up 
assessment was 1.0 year in median and might not be long enough to reveal significant associations. 
The follow-up of the SLAS (Study IV) is ongoing and future data may provide more evidence 
regarding the temporality.  
 
Although emergent evidence supports the association of stress and airway obstruction, the underlying 
mechanism is poorly understood. Stress response is complicated which involves the interaction of 
multiple psychobiological, genetic, and environmental factors from multiple systems. We believe that 
the work presented in this thesis could add a little more to the growing knowledge of the 
psychological and neuroendocrine response pattern to stress in individuals with airway obstructive 
diseases. We postulate that future multidisciplinary studies using neurochemical, neuroimaging, and 
genetic approaches may be helpful for elucidating a full picture of the genotype, phenotype, and 
psychobiological responses to stress. Since its discovery 30 years ago, the role of NPY in multiple 
pathophysiological processes such as cardiovascular diseases, stress, and obesity has drawn attention 
from researchers, and preliminary findings have been accumulating. Hopefully, related research 
could clarify the role of NPY in stress which is involved in a neurobiological response promoting 
resilience to psychological stress in the near future. In the long run, substantial progress in research 
findings is urgently needed to enhance the capabilities of human beings to predict, prevent, and treat 
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Asthma Control Questionnaire 
 
Please circle ONE answer for each of the five questions below. Be sure to review your results with 
your healthcare professional.  
 
1. In the past four weeks, 
how much of the time did 
your asthma keep you 
from getting as much 
done at work or at home? 
5). none of  
   the time    
4). a little 
of the time    
3). some of     
   the time  
2). most of    
  the time    
1). all of     
  the time 
2. During the past four 
weeks, how often have 
you had shortness of 
breath? 
5). not at  
     all 
 
4). once or   
twice a  
week 
3). 3 to 6  
   times a   
   week 
2). once a   
   day 
1). more 
than once a  
   day 
3. During the past four 
weeks, how often did your 
asthma symptoms 
(wheezing, coughing, 
shortness of breath, chest 
tightnss or pain) wake you 
up at night, or earlier than 
usual in the morning? 
5). not at  
     all 
4). once or   
    Twice 
3). once a  
    week 
2). 2 to 3  
  nights a  
  week 
1). 4 or  
  more  
  nights a  
  week 
4. During the past four 
weeks, how often have 
you used your rescue 
inhaler or nebulizer 
medication (such as 
albuterol)? 
5). not at  
     all 
4). once a   
   week or  
   less 
3). a few  
times a  
week 
2). 1 or 2 
times per   
  day 
1). 3 or 
more times 
per day 
5. How would you rate your 
asthma control during the 



















Revised Child Anxiety and Depression Scale 
 
Please put a circle around the word that shows how often each of these things happen to you. There 






1. I worry about things 0 1 2 3 
2. I feel sad or empty 0 1 2 3 
3. When I Have a problem, I get a dummy feeling in my stomach 0 1 2 3 
4. I worry when I think I have done poorly at something 0 1 2 3 
5. I would feel afraid of being on my own at home 0 1 2 3 
6. Nothing is much fun anymore 0 1 2 3 
7. I feel scared when I have to take a test 0 1 2 3 
8. I feel worried when I think someone is angry at me 0 1 2 3 
9. I worry about being away from my parents 0 1 2 3 
10.I get bothered by sad or silly thoughts or pictures in my mind 0 1 2 3 
11.I have trouble sleeping 0 1 2 3 
12.I worry that I will do badly at my school work 0 1 2 3 
13.I worry that something awful will happen to someone in my 
family 
0 1 2 3 
14.I suddenly feel as if I can’t breathe when there is no reason for 
this 
0 1 2 3 
15.I have problems with my appetite 0 1 2 3 
16.I have to keep checking that I have done things right (like the 
switch is off, or the door is locked) 
0 1 2 3 
17.I feel scared if I have to sleep on my own 0 1 2 3 
18. I have trouble going to school in the mornings because I feel 
nervous or afraid 
0 1 2 3 
19.I have no energy for things 0 1 2 3 
20.I worry I might look foolish 0 1 2 3 
21.I am tired a lot 0 1 2 3 
22.I worry that bad things will happen to me 0 1 2 3 




24.When I have a problem, my heart beats really fast 0 1 2 3 
25.I cannot think clearly 0 1 2 3 
26. I suddenly start to tremble or shake when there is no reason for 
this 
0 1 2 3 
27.I worry that something bad will happen to me 0 1 2 3 
28.When I have a problem, I feel shaky 0 1 2 3 
 Never Sometimes Often Always 
29.I feel worthless 0 1 2 3 
30.I worry about making mistakes 0 1 2 3 
31.I have to think of special thoughts (like numbers or words) to 
stop bad things from happening 
0 1 2 3 
32.I worry that other people think of me 0 1 2 3 
33.I am afraid of being in crowded places (like shopping centers, 
the movies, buses, usy playgrounds) 
0 1 2 3 
34.All of a sudden I feel really scared for no reason at all 0 1 2 3 
35.I worry about what is going to happen 0 1 2 3 
36.I suddenly become dizzy or faint when there is no reason for 
this 
0 1 2 3 
37.I think about death 0 1 2 3 
38.I feel afraid if I have to talk in front of my class 0 1 2 3 
39.My heart suddenly starts to beat too quickly for no reason 0 1 2 3 
40.I feel like I don’t want to move 0 1 2 3 
41.I worry that I will suddenly get a scared feeling when there is 
nothing to be afraid of 
0 1 2 3 
42.I have to do some things over and over again (like washing my 
hands, cleaning or putting things in a certain order) 
0 1 2 3 
43.I feel afraid that I will make a fool of myself in front of people 0 1 2 3 
44.I have to do some things in just the right way to stop bad things 
from happening 
0 1 2 3 
45.I worry when I go to bed at night 0 1 2 3 
46.I would feel scared if I had to stay away from home overnight 0 1 2 3 





Hospital Anxiety and Depression Scale (HADS) 
 
Please circle one answer that suits you most from the four given for each question. Give an immediate 
response and do not thinking too long about the answers. 
 
A I feel tense or 'wound up':  
 Most of the time 3 
 A lot of the time 2 
 From time to time, occasionally 1 
 Not at all 0 
 
D I still enjoy the things I used to 
enjoy: 
 
 Definitely as much 0 
 Not quite so much 1 
 Only a little 2 
 Hardly at all 3 
 
A I get a sort of frightened feeling 
as if something awful is about to 
happen: 
 
 Very definitely and quite badly  3 
 Yes, but not too badly  2 
 A little, but it doesn't worry me  1 
 Not at all 0 
 
D I can laugh and see the funny 
side of things: 
 
 As much as I always could  0 
 Not quite so much now  1 
 Definitely not so much now  2 
 Not at all  3 
 






 A great deal of the time  3 
 A lot of the time  2 
 From time to time, but not too often 1 
 Only occasionally 0 
 
D I feel cheerful:  
 Not at all  3 
 Not often  2 
 Sometimes  1 
 Most of the time 0 
 
A I can sit at ease and feel relaxed:  
 Definitely  0 
 Usually  1 
 Not Often 2 
 Not at all 3 
 
D I feel as if I am slowed down:  
 Nearly all the time  3 
 Very often  2 
 Sometimes  1 
 Not at all 0 
 
A I get a sort of frightened feeling 
like 'butterflies' in the stomach: 
 
 Not at all  0 
 Occasionally  1 
 Quite Often  2 
 Very Often 3 
 






 Definitely  3 
 I don't take as much care as should 2 
 I may not take quite as much care 1 
 I take just as much care as ever 0 
 
A I feel restless as I have to be on 
the move: 
 
 Very much indeed  3 
 Quite a lot  2 
 Not very much  1 
 Not at all 0 
 
 
D I look forward with enjoyment to 
things: 
 
 As much as I ever did  0 
 Rather less than I used to  1 
 Definitely less than I used to  2 
 Hardly at all  3 
 
A I get sudden feelings of panic:  
 Very often indeed  3 
 Quite often  2 
 Not very often  1 
 Not at all  0 
 
D I can enjoy a good book or radio or TV 
program: 
 
 Often  0 
 Sometimes  1 
 Not often  2 





The Holmes-Rahe Social Readjustment Ratings Scale (for children) 
 
Please put a circle around the word that happened to you during the last year in the following list. 
 
 Yes No 
1.Getting married  1 0 
2.Unwed pregnancy  1 0 
3.Death of parent 1 0 
4.Acquiring a visible deformity  1 0 
5.Divorce of parents 1 0 
6.Fathering an unwed pregnancy  1 0 
7.Becoming involved with drugs or alcohol  1 0 
8.Jail sentence of parent for over one year  1 0 
9.Marital separation of parents 1 0 
10.Death of a brother or sister 1 0 
 
11.Change in acceptance by peers 1 0 
12.Pregnancy of unwed sister  1 0 
13.Discovery of being an adopted child 1 0 
14.Marriage of parent to step-parent 1 0 
15.Death of a close friend 1 0 
16.Having a visible congenital deformity 1 0 
17.Serious illness requiring hospitalization  1 0 
18.Failure of a grade in school 1 0 
19.Not making an extracurricular activity  1 0 
20.Hospitalization of a parent 1 0 
 
21.Jail sentence of parent for over 30 days 1 0 
22.Breaking up with boyfriend or girlfriend 1 0 




24.Suspension from school 1 0 
25.Birth of a brother or sister 1 0 
26.Increase in arguments between parents 1 0 
27.Loss of job by parent  1 0 
28.Outstanding personal achievement  1 0 
29.Change in parent's financial status 1 0 
30.Accepted at a college of your choice 1 0 
 
31.Being a senior in high school 1 0 
32.Hospitalization of a sibling 1 0 
33.Increased absence of parent from home  1 0 
34.Brother or sister leaving home 1 0 
35.Addition of third adult to family 1 0 
36.Becommg a full fledged member of a church  1 0 
37.Decrease in arguments between parents 1 0 
38.Decrease in arguments with parents 1 0 





The Holmes-Rahe Social Readjustment Ratings Scale 
 
Please put a circle around the word that happened to you during the last year in the following list. 
 
 Yes No 
1. Death of a Spouse 1 0 
2. Divorce 1 0 
3. Marital Separation 1 0 
4. Imprisonment 1 0 
5. Death of a Close Family Member 1 0 
6. Personal Injury or Illness 1 0 
7. Marriage 1 0 
8. Dismissal from Work 1 0 
9. Marital Reconciliation 1 0 
10. Retirement 1 0 
 
11. Change in Health of Family Member 1 0 
12. Pregnancy 1 0 
13. Sexual Difficulties 1 0 
14. Gain a New Family Member 1 0 
15. Business Readjustment 1 0 
16. Change in Financial State 1 0 
17. Change in Frequency of Arguments 1 0 
18. Major Mortgage 1 0 
19. Fore closure of Mortgage or Loan 1 0 
20. Change in Responsibilities at Work 1 0 
 
21. Child Leaving Home 1 0 
22. Trouble with In-Laws 1 0 




24. Spouse Starts or Stop Work 1 0 
25. Begin or End School 1 0 
26. Change in Living Conditions 1 0 
27. Revision of Personal Habits 1 0 
28. Trouble with Boss 1 0 
29. Change in Working Hours or Conditions 1 0 
30. Change in Residence 1 0 
 
31. Change in Schools 1 0 
32. Change in Recreation 1 0 
33. Change in Church Activities 1 0 
34. Change in Social Activities 1 0 
35. Minor Mortgage or Loan 1 0 
36. Change in Sleeping Habits  1 0 
37. Change in Number of Family Reunions 1 0 
38. Change in Eating Habits 1 0 
39. Vacation 1 0 
40. Christmas 1 0 





Perceived Stress Scale (PSS) 
 
These questions ask you about your feelings, thoughts and activities during the last month, 
including today.  
 
In the last month, how often have you:  
 






1. Been upset because of something that happened 
unexpectedly? 
0 1 2 3 4 
2. Felt that you were unable to control important things 
in your life? 
0 1 2 3 4 
3. Felt nervous and "stressed"? 0 1 2 3 4 
4. Felt confident about your ability to handle your 
personal problems? 
0 1 2 3 4 
5. Felt that things were going your way? 0 1 2 3 4 
6. Found that you could not cope with all things you 
had to do? 
0 1 2 3 4 
7. Been able to control irritations in your life? 0 1 2 3 4 
8. Felt that you were on top of things? 0 1 2 3 4 
9. Been angered because of things that happened that 
were out of your control? 
0 1 2 3 4 
10. Felt difficulties were piling up so high that you could 
not overcome them? 









Pediatric Asthma Quality of Life Questionnaire 
 
We want you to tell us how much you have been bothered doing these things during the last week 
because of your asthma. 
 
Circle in the box that best describes how bothered you have been. 
 


























1 2 3 4 5 6 7 0 
2.Running 1 2 3 4 5 6 7 0 
3.Sleeping 1 2 3 4 5 6 7 0 
4.Coughing 1 2 3 4 5 6 7 0 
 
IN GENERAL, HOW OFTEN DURING THE LAST WEEK DID YOU: 






















5. Feel FRUSTRATED because of 
your asthma? 
1 2 3 4 5 6 7 
6. Feel TIRED because of your 
asthma? 
1 2 3 4 5 6 7 
7. Feel WORRIED, CONCERNED 
OR TROUBLED because of your 
asthma? 
1 2 3 4 5 6 7 
 





















8. Asthma Attacks? 1 2 3 4 5 6 7 
 
IN GENERAL, HOW OFTEN DURING THE LAST WEEK DID YOU: 


















9. Feel ANGRY because 
    of your asthma? 



























10. Wheezing 1 2 3 4 5 6 7 
 
IN GENERAL, HOW OFTEN DURING THE LAST WEEK DID YOU: 






















11. Feel IRRITABLE / Grumpy 
because of your asthma? 
1 2 3 4 5 6 7 
 





















12. Tightness in your chest 1 2 3 4 5 6 7 
 
IN GENERAL, HOW OFTEN DURING THE LAST WEEK DID YOU: 






















13. Feel different or left out 
because of your asthma?  
1 2 3 4 5 6 7 
 
HOW BOTHERED HAVE YOU BEEN DURING THE LAST WEEK DID YOU: 




















14. Shortness of breath 1 2 3 4 5 6 7 
 
IN GENERAL, HOW OFTEN DURING THE LAST WEEK DID YOU: 






















15. Feel FRUSTRATED because 
you couldn’t KEEP UP with 
others? 
1 2 3 4 5 6 7 
16. WAKE UP during the NIGHT 
because of your asthma?  




17. Feel UNCOMFORTABLE 
because of your asthma? 
1 2 3 4 5 6 7 
18. Feel OUT OF BREATH 
because of your asthma?  
1 2 3 4 5 6 7 
19. Feel you COULDN’T KEEP 
UP WITH OTHERS because of 
your asthma? 
1 2 3 4 5 6 7 
20. Have TROUBLE SLEEPING 
at night because of your asthma? 
1 2 3 4 5 6 7 
21. Feel FRIGHTENED by an 
ASTHMA attack? 
1 2 3 4 5 6 7 
 





















22. How much were you 
bothered by your asthma 
during these activities? 
1 2 3 4 5 6 7 
 
IN GENERAL, HOW OFTEN DURING THE LAST WEEK DID YOU: 






















23. Have difficulty taking a DEEP 
BREATH? 





Asthma Quality of Life Questionnaire 
 
Tick activities in which you are limited by asthma during the last 2 week from the following list. If 
you are limited in more than 5 activities because of asthma, choose 5 activities you are most 
bothered. 
 
1 Bicycling 14 Shovelling snow 
2 Clearing snow off your car 15 Singing 
3 Dancing 16 Doing regular social activities 
4 Doing home maintenance 17 Having sexual intercourse 
5 Doing housework 18 Talking 
6 Gardening 19 Running upstairs or uphill 
7 Hurrying 20 Vacuuming 
8 Jogging, excercising, or running 21 Visiting friends or relatives 
9 Laughing 22 Going for a walk 
10 Mopping or scrubbing the floor 23 Walking upstairs or uphill 
11 Mowing the lawn 24 Woodwork or carpentry 
12 Playing with pets 25 Carrying out your activities at work 
13 Playing sports   
 
Fill in the blanks of the following 5 questions with the activities you chose above, then answer the 


























1. Please indicate how much 
you have been limited by 
your asthma in                   ?           
1 2 3 4 5 6 7 
1. Please indicate how much 
you have been limited by 
your asthma in                   ?           
1 2 3 4 5 6 7 
3. Please indicate how much 
you have been limited by 
your asthma in                   ?           
1 2 3 4 5 6 7 
4. Please indicate how much 
you have been limited by 
your asthma in                   ?           
1 2 3 4 5 6 7 
5. Please indicate how much 
you have been limited by 
your asthma in                   ?           






Tick the answer that best suits you for the following questions. 
 
6. How much discomfort or 
distress have you felt over the last 


















1 2 3 4 5 6 7 
 





















7. In general, how often 
during the last 2 weeks have 
you felt concerned about 
having asthma? 
1 2 3 4 5 6 7 
8. How often during the past 
2 weeks did you feel short of 
breath as a result of your 
asthma? 
1 2 3 4 5 6 7 
9. How often during the past 
2 weeks did you experience 
asthma symptoms as a result 
of being exposed to cigarette 
smoke? 
1 2 3 4 5 6 7 
10. How often during the 
past 2 weeks did you 
experience a wheeze in your 
chest? 
1 2 3 4 5 6 7 
11. How often during the 
past 2 weeks did you feel 
you had to avoid a situation 
or environment because of 
cigarette smoke? 
1 2 3 4 5 6 7 
 
 A very 














12. How much discomfort or 
distress have you felt over the past 
two weeks as a result of coughing? 



























13. How often during the past 
2 weeks did you feel 
frustrated as a result of your 
asthma? 
1 2 3 4 5 6 7 
14. How often during the past 
2 weeks did you experience a 
feeling of chest heaviness? 
1 2 3 4 5 6 7 
15. How often during the past 
2 weeks did you feel 
concerned about the need to 
take medication for your 
asthma? 
1 2 3 4 5 6 7 
16. How often during the past 
2 weeks did you feel the need 
to clear your throat? 
1 2 3 4 5 6 7 
17. How often during the past 
2 weeks did you experience 
asthma symptoms as a result 
of 
being exposed to dust? 
1 2 3 4 5 6 7 
        





















18. How often during the past 
2 weeks did you experience 
difficulty breathing out as a 
result of your asthma? 
1 2 3 4 5 6 7 
19. How often during the past 
2 weeks did you feel you had 
to avoid a situation or 
environment because of dust? 
1 2 3 4 5 6 7 
20. How often during the past 
2 weeks did you wake up in 
the morning with asthma 
symptoms? 
1 2 3 4 5 6 7 
21. How often during the past 
2 weeks did you feel afraid of 
not having your asthma 
medication available? 





22. How often during the past 
2 weeks were you bothered by 
heavy breathing? 
1 2 3 4 5 6 7 
23. How often during the past 
2 weeks did you experience 
asthma symptoms as a result 
of the weather or air pollution 
outside? 
1 2 3 4 5 6 7 
24. How often during the past 
2 weeks have you been woken 
at night by your asthma? 
1 2 3 4 5 6 7 
25. How often during the past 
2 weeks have you had to avoid 
or limit going outside because 
of the weather or air pollution? 
1 2 3 4 5 6 7 
26. How often during the past 
2 weeks did you experience 
asthma symptoms as a result 
of being exposed to strong 
smells or perfume? 
1 2 3 4 5 6 7 
27. How often during the past 
2 weeks did you feel afraid of 
getting out of breath? 
1 2 3 4 5 6 7 
28. How often during the past 
2 weeks did you feel you had 
to avoid a situation or 
environment because of strong 
smells or perfume? 
1 2 3 4 5 6 7 
29. How often during the past 
2 weeks has your asthma 
interfered with getting a good 
night's sleep? 
1 2 3 4 5 6 7 
30. How often during the past 
2 weeks have you had the 
feeling of fighting for air? 






























Not limited at 
all-have done 
all activities 
that I wanted 
to do 

















1 2 3 4 5 6 7 
 
 Totally limited, 
couln’t do 




















32. Overall, among 
all the activities that 
you have done 
during the past 2 
weeks, how limited 
have you been by 
your asthma?  









Disagree Neutral Agree Strongly 
Agree 




2 3 4 
2. I often feel inferior to others. 
 
0 1 2 3 4 
3. When I’m under a great deal of stress, sometimes I 
feel like I’m going to pieces. 
0 1 2 3 4 
4. I rarely feel lonely or blue. 
 
0 1 2 3 4 
5. I often feel tense and jittery. 
 
0 1 2 3 4 
6. Sometimes I feel completely worthless. 
 
0 1 2 3 4 
7. I rarely feel fearful or anxious. 
 
0 1 2 3 4 
8. I often get angry at the way people treat me. 
 
0 1 2 3 4 
9. Too often, when things go wrong, I get discouraged 
and feel like giving up. 
0 1 2 3 4 
10. I am seldom sad or depressed. 
 
0 1 2 3 4 
11. I often feel helpless and want someone else to solve 
my problems. 
0 1 2 3 4 
12. At times I have been so ashamed I just wanted to 
hide. 
0 1 2 3 4 
 
